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Abstract 
 
Staphylococcus aureus has long been recognized as a leading cause of nosocomial 
infection.  However, several recent publications have demonstrated this pathogen as the 
cause of community-acquired severe wound infections and necrotizing pneumonia in 
otherwise healthy individuals.  These highly virulent endemic clones have been reported 
in several locations in the United States and Canada. The rapid spread of the organism, 
the ability of certain clones to cause serious infection, and the antibiotic resistance of the 
endemic clones, illustrates the importance of infection control measures.   In this study 
we examined three S. aureus typing techniques; pulsed-field gel electrophoresis (PFGE), 
multilocus sequence typing (MLST), and Staphylococcal protein A (spa) sequencing for 
subspeciation of community-acquired methicillin-resistant S. aureus (CA-MRSA).    It is 
hypothesized that PFGE will result in a higher level of discrimination among the strains, 
while MLST and spa typing will result in highly portable data that lacks the 
discriminatory power of PFGE.  Thirty CA-MRSA isolates that were obtained from 
Florida and Washington State were characterized by molecular typing methods.  Whole 
genome restriction analysis was performed by PFGE using the SmaI enzyme.  Sequence-
vii 
based typing analyses, MLST and spa typing, were performed by polymerase chain 
reaction (PCR) followed by sequencing.  PFGE data was analyzed using the 
BioNumerics® software package and sequence-based data was analyzed using 
DNAstar®.   MLST Alleles were assigned using the online MLST database 
(www.mlst.net) and spa types were assigned using the Ridom SpaServer 
(www.ridom.de/spaserver).  Molecular characterization of the 30 isolates resulted in 21 
pulsotypes, four MLST sequence types (STs), and six spa types.  Combining data from 
both MLST and spa typing resulted in only seven strain categories, many of which 
grouped isolates that are not epidemiologically linked.  These data demonstrate that 
techniques such as MLST and spa typing are not well suited for tracking isolates with 
limited evolutionary diversity such as the CA-MRSA epidemic clones. 
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Introduction 
 
Impact of Staphylococcus aureus 
 
 Staphylococcus aureus is a Gram positive, nonmotile cocci that is one of the 
leading causes of nosocomial infection.  Approximately 2% of all patients admitted to the 
hospital will develop S. aureus infection (66), which is a major public health concern due 
to the associated morbidity, mortality, and cost of care.  Infection with S. aureus results 
in twice the length of stay, deaths, and medical costs as compared to patients without 
infection who are receiving the same treatment (94).  The average cost of hospital stay in 
a study of patients in New York City hospitals was $13,263 without complications versus 
$32,100 for patients with hospital-acquired S. aureus infection (94).  Furthermore, the 
economic impact is increasing due to the spread of antibiotic resistance, particularly 
methicillin resistance, among S. aureus isolates. A 2004 report from the National 
Nosocomial Infections Surveillance (NNIS) System, a network of healthcare agencies 
which report nosocomial infection surveillance data, demonstrated that nearly 60% of all 
S. aureus isolates in US hospitals are methicillin resistant (11). The cost of treating 
infections caused by methicillin-resistant S. aureus (MRSA) is approximately $2,500 
more than treating susceptible S. aureus due to the increased length of stay and more 
expensive antibiotic treatment (94). 
Among the many types of disease caused by S. aureus are localized skin 
infections including carbuncles, furuncles, impetigo, and sties, and one disseminated skin 
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condition known as scalded skin syndrome.  More serious conditions caused by S. aureus 
include septicemia, wound infection, post-surgical infection, pneumonia, osteomyelitis, 
toxic shock syndrome, and endocarditis (96).  NNIS surveillance data from 1990 to 1996 
demonstrated that S. aureus was the most common cause of nosocomial pneumonia and 
surgical site infection, and the second leading cause of nosocomial bloodstream 
infections (10).   Furthermore, S. aureus is one of the leading causes of food-borne illness 
(63).   Most cases of food-borne illness result from the toxin produced by the organism 
and therefore there is little surveillance data to elucidate the true contribution of S. aureus 
to the estimated 76 million cases of food-borne illness that occur annually in the United 
States (63).  However, in at least one documented case, MRSA organism was spread 
from a food handler to restaurant patrons via the gastrointestinal route (52).    
S. aureus is found in the anterior nares of both adults and children with 
approximately one-third of the population colonized during any given time (19, 67, 85).   
Among the carriers, between three and 10% of individuals will be colonized with MRSA 
(19, 46, 67, 85).  The rates of MRSA carriage are highest among individuals with human 
immunodeficiency virus (HIV), intravenous drug users, patients with open abscesses, and 
those persons who were recently hospitalized (85).  However, the number of children 
colonized with MRSA, who have no potential risk factors for MRSA carriage, has 
increased significantly in the past four years (19, 46).  The emergence of these 
community-acquired MRSA (CA-MRSA) strains is of particular concern because 
colonization typically precedes infection, with greater than 80% of infecting isolates 
originating from the nose (18, 19).  Asymptomatic carriers of S. aureus can be a source of 
3 
spread of the organism in both the community and hospital setting.  However, not all S. 
aureus strains are equal in their ability to cause serious disease. 
Staphylococcus aureus Pathogenesis 
 Complete genome sequencing has been performed on seven S. aureus strains, 
including four MRSA isolates.   Comparison of these genomes indicates that S. aureus 
has a stable core of vertically transmitted genes, present in all seven genomes, but also 
frequently acquires genes by horizontal transfer (66).  Approximately 25% of the S. 
aureus genome consists of genes that are horizontally transferred by mobile elements 
including bacteriophages, chromosomal cassettes, plasmids, and transposons (66).  Many 
of these genes encode virulence and resistance determinants (44, 66).  Further 
information on these determinants has been elucidated by comparison of the seven S. 
aureus genomes to a related but less pathogenic species, Staphylococcus epidermidis 
(66).  These studies suggest that the pathogenesis of S. aureus is largely due to the 
presence of MSCRAMMS (microbial surface components recognizing adhesive matrix 
molecules), capsule production, antibiotic resistance genes, and toxins (66, 96). 
 MSCRAMMS are bacterial proteins present in a number of pathogenic organisms 
that aid in binding to human tissues and artificial surfaces.  MSCRAMMS have been 
identified in S. aureus that bind to fibronectin, fibrinogen, and collagen components of 
the host cell wall (35).   Most strains produce two fibronectin binding proteins, FnBPA 
and FnBPB which are involved in host cell attachment and binding to plasma clots and to 
artificial surfaces (35).  Fibrinogen binding is mediated by two proteins, ClfA and ClfB, 
that are not only involved in the same attachment processes as the fibronectin-binding 
proteins, but also seem to have a role in endocarditis (35).  Collagen binding, mediated by 
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the Cna protein, is not a characteristic of most isolates.  However, Cna is necessary for 
binding to collagen and therefore has an important role in septic arthritis caused by S. 
aureus (35).    
 The classical experiments by Griffith illustrating the genetic transformation 
principle using Streptococcus pneumoniae also demonstrated the role of the bacterial 
capsule in pathogenesis.   These experiments demonstrated that unencapsulated non-
virulent S. pneumoniae isolates could “acquire” the ability to form capsule if mixed with 
encapsulated strains and these strains could then cause pneumonia in a mouse model (68).  
Although considered a seminal contribution to the field of genetics, this experiment also 
highlighted the role of the capsule in S. pneumoniae virulence.  Although often 
overlooked as a virulence factor, it is of particular note that all of the organisms 
responsible for septic meningitis, Neisseria meningitidis, S. pneumoniae, and 
Haemophilus influenzae produce polysaccharide capsules (96).  The S. aureus capsule 
has several roles in pathogenesis including host cell binding via MSCRAMMS as 
described above, biofilm formation, and immune system avoidance.  Although the 
MSCRAMMS likely play a role in biofilm formation, a number of capsular genes are 
also involved (35, 96).   The type of capsule present on a particular strain, determining 
the serotype of that isolate, has been related to virulence (118).  Finally, the 
staphylococcal protein A component of the S. aureus capsule has been shown to bind to 
antibodies without leading to lysis of the cell (96).  This antibody coat may allow the 
organism to escape the immune response (96).    
 One of the most well studied areas of S. aureus pathogenesis is its array of 
antibiotic resistance genes.  The organism has acquired resistance by mutation of genes 
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on the chromosome as well as transfer of resistance determinants from other organisms 
by conjugation, transformation, and transduction (44, 51, 62).  Although resistance to 
many antibiotics is common in S. aureus, methicillin resistance is of particular concern 
due to its public health impact in terms of mortality, morbidity, and cost.  MRSA was 
reported in European hospitals in the early 1960s immediately following the introduction 
of methicillin to clinical practice (13).  Resistance occurs in these isolates due to the 
production of a penicillin-binding protein, PBP 2a, that has a low affinity for binding β-
lactam antibiotics (13).  The PBP 2a protein thus performs the cell growth functions of 
the high-affinity proteins while simultaneously providing the cell resistance to an entire 
class of antibiotics (13).  Phylogenetic studies have demonstrated that genetic exchange 
has resulted in S. aureus acquiring methicillin resistance at least five times since the first 
isolates were described in 1960, (20, 27, 28, 31, 32) and MRSA isolates have since 
spread worldwide (1, 5, 15, 25, 37, 56, 58, 87, 102, 110, 122).   
 S. aureus isolates differ in their ability to cause disease due in part to the 
expression of toxin genes present in their genome. Certain toxins such as Panton-
Valentine Leukocidin (PVL) are known to cause necrotizing pneumonia and wound 
infections (36, 39, 50, 65, 117), while others such as Staphylococcal enterotoxin A and B 
are related to food poisoning (55, 57, 63, 69, 96, 99, 104).  Many of the S. aureus toxin 
genes reside in four Staphylococcal pathogenicity islands (SaP1 – SaP4) along with other 
virulence factors while some of the genes are phage or plasmid encoded (66).  A 
summary of staphylococcal toxin genes and their function is shown in Table 1. 
 
 
TABLE 1.  Summary of S. aureus toxin genes 
Gene Location and Function Reference 
sea Phage encoded – superantigen – food poisoning Klotz et al. (2003) 
seb SaP1 – superantigen – food poisoning Klotz et al. (2003) 
sec1,2,3  SaP2 – 3 related superantigens – food poisoning Klotz et al. (2003) 
sed Plasmid encoded – superantigen – food poisoning Klotz et al. (2003) 
see Phage encoded – superantigen – food poisoning Klotz et al. (2003) 
seg Phage encoded – superantigen – gastrointestinal syndrome Klotz et al. (2003) 
seh Superantigen – gastrointestinal syndrome Klotz et al. (2003) 
sei SaP3 – superantigen – gastrointestinal syndrome Klotz et al. (2003) 
sej Plasmid encoded – superantigen – unknown function Sumby et al. (2003) 
sek Phage encoded – superantigen – unknown function Seergev et al. (2004) 
sel  SaP2 – superantigen – food poisoning Seergev et al. (2004) 
sem SaP3 – superantigen – unknown function Klotz et al. (2003) 
sen SaP3 – superantigen – unknown function Klotz et al. (2003) 
seo SaP3 – superantigen – unknown function Klotz et al. (2003) 
sep Phage encoded – superantigen – food poisoning Kuroda et al. (2001) 
seq SaP1 – superantigen – unknown function Seergev at al. (2004) 
seu Superantigen – unknown function Klotz et al. (2004) 
TSST SaP1 – toxic shock syndrome toxin Salyers et al. (2002) 
eta Phage encoded – exfoliative toxin, scalded skin syndrome Salyers et al. (2002) 
etb Phage encoded – exfoliative toxin, scalded skin syndrome Salyers et al. (2002) 
hla Gamma hemolysin component– red blood cell lysis Kuroda et al. (2001) 
hlb Gamma hemolysin component – red blood cell lysis Kuroda et al. (2001) 
hld Alpha hemolysin – red blood cell lysis and tissue necrosis Kuroda et al. (2001) 
lukS Phage encoded – PVL – pneumonia, etc. Gillet et al. (2002) 
lukF Phage encoded – PVL – pneumonia, etc. Gillet et al. (2002) 
 
 
 
Role of S. aureus in Bioterrorism  
 The deliberate contamination of food products with microbial agents including 
organisms and/or their toxins is a distinct possibility due to the complexity of the food 
service industry (63).  Food is particularly vulnerable during the processing, preparation, 
and delivery stages (63).  Staphylococcal enterotoxin B (SEB), considered a select agent, 
can be used to contaminate food or low-volume water supplies, or alternatively it can be 
administered as an aerosol (63, 93).  Contamination of food supplies with SEB is a low-
tech means of incapacitating a large number of people by simultaneously inducing an 
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outbreak of vomiting and diarrhea.  In addition to these symptoms, typical S. aureus 
food-borne intoxication includes fever, chills, headache, non-productive cough, and 
shortness of breath (93).   In most cases, the gastrointestinal symptoms clear quickly and 
full recovery is likely, but the cough is long-lasting and persons are usually incapacitated 
for up to two weeks (93).  S. aureus food poisoning could therefore be a useful tactic to a 
terrorist who wishes to do economic damage to a particular company or to induce panic 
in a particular population.    
A more deadly scenario occurs when SEB is aerosolized.  Studies have shown 
that SEB acts as a superantigen that activates T-cells leading to the release of massive 
amounts of cytokines within the respiratory mucosa which can lead to death by severe 
pulmonary edema (69).  Although this route of exposure is unlikely due to the technical 
issues involved in mass production and aerosolizing SEB, just a few hundred cases would 
overwhelm the capacities of most local medical institutions to provide ventilation support 
(69, 93).   
Although most research has focused on the detection of SEB in food products 
both for bioterrorism detection (55) and food-borne illness detection (99), the other S. 
aureus toxins should also be considered as possible bioweapons.  The majority of food-
borne illness outbreaks are due to staphylococcal enterotoxin A (SEA) and newly 
described enterotoxins elicit a gastrointestinal syndrome in mouse models (57).  
Furthermore, S. aureus isolates capable of causing serious disease contain various 
combinations of toxin genes, and many isolates do not contain seb genes.   Therefore 
detection methods for S. aureus intoxication should include a wide variety of toxins (99).      
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Community-acquired Methicillin-Resistant S. aureus (CA-MRSA) 
 MRSA has been circulating in hospitals since the early 1960s but reports of 
infection in the community were relatively rare.  However, in the early 1990s strains of 
highly virulent CA-MRSA were reported in Western Australia (112).  In recent years the 
incidence of CA-MRSA has been increasing with outbreaks occurring in the United 
States (5, 7, 12, 14, 37, 54, 70, 71, 79, 81, 112), Canada (77), and overseas (2, 25, 36, 39, 
110).  CA-MRSA strains differ from hospital-acquired MRSA (HA-MRSA) in their 
antibiotic resistance profiles, their virulence determinants, and their ability to cause 
disease in patients without traditional risk factors (24, 43, 119).   
 Methicillin resistance in S. aureus is encoded by the mecA gene located in the 
staphylococcal cassette chromosome mec (SCCmec) region.  This region also contains 
the regulatory and recombinase genes.  Several different SCCmec complexes have been 
described that contain insertions and deletions in the regulatory and recombinase genes 
(3, 64).   CA-MRSA strains frequently carry variants of the SCCmec IV element, the 
smallest of the known SCCmec elements (2, 3, 64, 116).  This finding has lead to a 
number of hypotheses concerning the spread of the CA-MRSA isolates.  While one group 
believes that CA-MRSA isolates evolved from HA-MRSA (2), another introduces the 
differences in SCCmec complexes as evidence that CA-MRSA and HA-MRSA are in fact 
not related (116).  Interestingly, the same studies report different results when comparing 
growth rates of CA-MRSA and HA-MRSA strains.  In two studies CA-MRSA isolates 
displayed a faster doubling time than the HA-MRSA isolates (116, 123) and the authors 
postulate that this occurs due to the small size of the SCCmec complex.  However, 
another study found no difference in growth rates between the two types of isolates (2).  
9 
Regardless of the evolutionary background of the isolates, it seems clear that MRSA is 
replacing methicillin-sensitive S. aureus (MSSA) in the community.   
Many CA-MRSA strains carry the genes for encoding PVL, a toxin involved in 
tissue necrosis (117).  Binding of PVL to neutrophils induces an immune cascade that 
includes secretion of degradative enzymes and generation of superoxide ions which 
promotes necrosis of tissue (123).  Several studies have demonstrated a link between 
PVL-producing S. aureus isolates and primary skin infections and necrotizing pneumonia 
(7, 12, 14, 25, 36, 37, 39, 50, 54, 61, 65, 71, 77), although other virulence factors many 
also play a role (95).  Pneumonia caused by PVL-positive CA-MRSA isolates has a high 
mortality rate as shown in a study of 23 patients in which 14 patients (61%) died from the 
disease (65).  Wound infections caused by similar isolates are not usually fatal but are 
often accompanied by serious complications such as the need for reconstructive surgery 
to reverse tissue damage and prolonged stays in the intensive care unit (71).   
Pulsed-field gel electrophoresis (PFGE) of 957 MRSA isolates resulted in the 
identification of eight major lineages of S. aureus strains known as USA 100 – USA 800 
(70).  While most were hospital-associated strains, USA 300 and USA 400 were 
associated with community-acquired infections (70).  Recent studies have indicated that 
these two clones are spreading rapidly and they are now referred to as epidemic clones.  
USA 300 epidemic clone has been reported as a cause of serious wound infections in 
football players in Missouri and Connecticut among otherwise healthy, young individuals 
(5, 54).  USA 300 is also responsible for the sharp increase in necrotizing wound 
infections reported in California (71) and may be responsible for another outbreak in 
California reported in the same time frame with similar epidemiology (75).  Alarmingly, 
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studies in Texas have also demonstrated the emergence of an epidemic clone among 
pediatric isolates in Houston and Dallas (14, 72, 81).  Although these studies did not 
provide conclusive evidence that the responsible clone is USA 300 in the form of pulsed-
field patterns, the antibiotic resistance data, epidemiological data, and the multilocus 
sequence type (MLST) 8, are all consistent with USA 300 and not USA 400 (14, 72, 81).  
The USA 400 epidemic CA-MRSA clone, which has a distinct PFGE pattern and 
multilocus sequence type, has been reported as the cause of wound infections in New 
York and Canada (7, 77).  Finally, a retrospective study of patient charts identified CA-
MRSA isolates in Georgia, Minnesota, and Maryland (37).  However, this study provided 
only antibiotic resistance data and the epidemic clones can not be differentiated without 
genomic subspeciation.   
 
Techniques for subtyping S. aureus  
 Bacterial subtyping is useful for a number of epidemiological and infection 
control practices including tracking the spread of strains of interest, determining isolates 
involved in outbreaks, monitoring trends in endemic isolates, and source tracking.  
Earlier techniques for subtyping S. aureus were phenotypic and biochemical in nature but 
many of these have been replaced with genomic techniques that offer higher 
discriminatory power.  The “Gold Standard” for typing S. aureus isolates is PFGE.   It 
has been shown to be more discriminatory than phenotypic techniques such as 
bacteriophage typing (4, 70), that is based on the susceptibility of certain strains for 
bacteriophage lysis detected by plaque assay, and antibiogram typing, based on antibiotic 
susceptibility patterns (48, 74).  Phage typing was used by the Centers for Disease 
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Control and Prevention (CDC) for many years to type S. aureus isolates as it had higher 
discriminatory power than other techniques available at the time, despite the fact that 
nearly 20% of isolates were non-typeable by this method (4).  The CDC has since 
replaced phage typing with pulsed-field typing for a number of organisms including S. 
aureus (4).  Likewise, PFGE has replaced many biochemical typing methods such as 
biotyping, which uses a panel of biochemical reactions to identify strains, capsular 
typing, based on serotyping using monoclonal antibodies, and zymotyping, based on the 
electrophoretic mobility patterns of esterases (97).   
Early molecular techniques used for S. aureus genotyping include plasmid profile 
analysis, whole genome restriction enzyme analysis (REA), and ribotyping.  Plasmid 
profile analysis is limited both by the number of isolates that lacked plasmids, and that 
plasmids are mobile and can therefore be lost (48).  REA is limited by the large number 
of fragments generated in the digest that results in overlapping fragments not separated 
by agarose gel electrophoresis (111).  Ribotyping, based on the use of probes to detect the 
ribosomal rRNA genes, has had mixed results in its use for typing S. aureus.  While the 
technique has been shown to be useful in a hospital outbreak of MSSA (82), it lacks the 
discriminatory power to differentiate MRSA strains (21, 82, 89, 111).   Many PCR-based 
techniques have also been used for S. aureus typing (103).  Multiplex PCR allows the 
rapid identification of MRSA versus MSSA isolates, but cannot identify strains (84).  
Hypervariable region PCR (HVR-PCR) can classify MSSA but cannot discriminate 
epidemic and sporadic MRSA (47, 98) and arbitrarily primed PCR (RAPD), has been 
useful in typing isolates from cattle (86, 111), but lacks the discriminatory power of 
PFGE for MRSA strains.  Some techniques that have excellent discriminatory power 
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include GeneChips and whole genome sequencing, but their use is restricted due to high 
cost, lengthy analysis, and required technical expertise (26, 51, 62, 66).   
Methicillin resistance in S. aureus is believed to have been acquired at least 5 
times since the 1960s and has spread throughout hospitals worldwide (27).  In contrast, 
community-acquired MRSA have only appeared in the last decade, a relative short time 
period on an evolutionary scale.  As such, CA-MRSA lacks the genetic diversity that is 
often seen in HA-MRSA (34).  Due to the fact that MRSA strains, and particularly CA-
MRSA strains were derived from relatively few clones, a typing technique must be used 
that has sufficient discriminatory power to differentiate the strains into epidemiologically 
related and non-related groups (107, 111).    
 
Pulsed-field Gel Electrophoresis for Subtyping Methicillin-Resistant S. aureus  
 The first step in PFGE involves embedding the microorganisms of interest in an 
agarose block to prevent shearing of the DNA during electrophoresis.  Immobilization 
allows the organisms to be lysed in situ followed by macrorestriction of the DNA using 
the restriction enzyme of choice.  The SmaI enzyme is used for S. aureus PFGE as it 
results in 10-20 fragments, depending on the isolate, which range in size from 10 to 700 
kb which can be easily separated on a PFGE gel (42).  The agarose “plugs” containing 
the restricted DNA are then loaded on the gel and an electrical current is applied.  The 
direction of the current (switch) is alternated during the electrophoresis to allow large 
fragments of DNA to align themselves with the current (108, 111).  The run time, 
voltage, and switch times are experimentally determined based on the size of the 
fragments generated by macrorestriction.  The resulting fingerprint patterns can be 
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visualized using ethidium bromide and analyzed either by sight and application of the 
Tenover criteria for strain typing (108), or by computer using BioNumerics®, 
GelCompar® or other software packages.  To date no S. aureus isolate has ever been 
reported that is non-typeable by PFGE and epidemiological data suggests that unique 
DNA fingerprint patterns are consistent with strain designations.    
 PFGE has been used for a wide variety of applications in healthcare institutions, 
research laboratories, public health laboratories, and other government laboratories.  The 
SENTRY program uses both PFGE and ribotyping to track multidrug-resistant bacteria in 
healthcare organizations (23).  PFGE can be used to track highly virulent, epidemic 
clones such as USA 300 and USA 400 (12, 70, 119).  DNA fingerprint patterns can be 
used to determine if particular strains are related to disease outcome (12, 70, 114, 119).  
In particular, the patterns may predict if strains are PVL positive and which SCCmec 
cassette they are carrying (121).  PFGE may also be used to compare methicillin-sensitive 
to methicillin-resistant strains (8).  One of the largest programs utilizing this technique is 
the PulseNet program at the CDC and worldwide.   
PulseNet is a network of public health laboratories that submit isolates involved in 
suspected food-borne illness outbreaks for molecular typing and comparison to other 
isolates in the database (105).  This technique has been used successfully to identify 
outbreaks, to determine the number of isolates involved, and to track the source of the 
outbreak (38, 90, 105).   PulseNet participants must use a standardized protocol and pass 
rigorous quality control training before they may submit samples to the database.  
Currently there exists no PulseNet database for S. aureus and no standardized protocol 
has been developed for S. aureus PFGE.  A recent publication suggests that CDC is 
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developing a database of S. aureus PFGE fingerprints aimed at tracking the CA-MRSA 
epidemic clones (70), however it is unclear if this database will be a part of PulseNet and 
therefore available for worldwide sample submission.  MRSA fingerprint databases do 
exist in Europe, Canada, and Australia and efforts to standardize protocols have been 
successful.  A protocol developed in Canada has shortened the S. aureus PFGE procedure 
from five days to 48 hours and laboratories using the procedure reported excellent 
reproducibility and interlaboratory comparison (76).  Similarly, a harmonized European 
protocol was tested by 10 laboratories in eight countries and demonstrated sufficient 
interlaboratory reproducibility to track epidemic MRSA strains in Europe (78).   
Although PFGE has been used for a number of applications, there are as many 
disadvantages as advantages to using the technique (Table 2) and other molecular 
techniques are under investigation.  
 
TABLE 2. Advantages and disadvantages of pulsed-field gel electrophoresis 
Advantages Disadvantages 
• Highly discriminatory • May be too discriminatory 
• Reproducible • Time-consuming 
• All strains can be typed • Expensive 
• Patterns are stable over time • Technically demanding 
• BioNumerics software allows 
comparison between 
laboratories 
• Interlaboratory comparison may be 
difficult as software is subjective 
• Demonstrated use in 
epidemiological studies 
• Need to store marker isolate 
• Not necessary to standardize 
DNA plug preparation 
procedure, type of agarose 
used, or plug digestion. 
• Must standardize cell 
concentrations, lysis conditions, 
PFGE equipment, electrophoresis 
conditions, run times, and analytical 
methods 
• Genomic Information not 
needed. 
• Need control strain on every gel 
 
 
15 
Multilocus Sequence Typing of S. aureus 
 Genome-based sequencing techniques have been explored as an alternative to gel-
based techniques such as PFGE to circumvent problems associated with cost, time, 
technical expertise required, and interlaboratory comparison of resulting data.  One of the 
more recent techniques used for molecular typing of S. aureus is multilocus sequence 
typing (MLST).  MLST was designed based on the principles of multilocus enzyme 
electrophoresis (MLEE) in which the electrophoretic mobilities of housekeeping enzymes 
of isolates of interest are compared (29).  In MLST, the gel analysis is bypassed by 
comparing nucleotides from housekeeping genes, chosen because they likely represent 
the stable core genome as opposed to virulence genes (31).  The number of housekeeping 
genes that must be sequenced depends on the organism typed and the genes used for the 
analysis.  Organisms such as Enterococcus faecalis can be typed using just two genes 
while typing of S. aureus requires seven housekeeping genes (29, 80).  A standardized 
protocol has been established for S. aureus MLST which requires amplification of the 
genes of interest, followed by sequencing of approximately 450 base pair fragments 
(http://saureus.mlst.net).  This fragment size was selected because the entire length of the 
fragment can easily be sequenced in either direction with just one reaction (113).   Each 
gene sequence is assigned an allele and the sequences of all seven genes make up an 
allelic pattern.  One of the major advantages of using MLST is that the gene sequences 
once resolved can be entered into the database and alleles assigned by comparison with 
sequences already entered.  The same principle allows allelic patterns to be assigned as 
sequence types (STs) if a match of all seven alleles exists in the database.  Therefore any 
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isolate that is typed can easily be compared to all previously typed isolates, allowing 
worldwide tracking of STs of interest (28).   
MLST was primarily designed for global epidemiology and the online database 
includes a phylogenic program, eBURST, that subdivides isolates that share high genetic 
similarity into clonal clusters (CCs) using allelic profile data (33).   Isolates within each 
clonal cluster share 100% genetic identity at six of seven loci with at least one other 
member of the group (32).   The founding genotype is identified parsimoniously as the 
genotype that differs from the highest number of other genotypes in the CC at only one 
locus and usually corresponds to a strain that is present in the population in high numbers 
due to increased fitness or random genetic drift (32, 33).  The eBURST program 
generates radial diagrams that can be used to address basic questions about the 
evolutionary and population biology of bacterial species (28).  S. aureus CCs are usually 
simple with a single founder surrounded by isolates with allelic profiles that differ from 
that of the founder in only one housekeeping gene, known as single locus variants (SLVs) 
(32).  This is especially true of MRSA because MLST assesses variations that accumulate 
slowly in the population and MRSA isolates have not had much time to accumulate 
variations in their housekeeping genes to distinguish them from their MSSA ancestors 
(28, 31).    
 The evolution of S. aureus and the acquisition of methicillin-resistance have been 
examined by a large number of MLST studies.  Comparison of isolates from carriers 
were identical to those with invasive disease suggesting that S. aureus disease-causing 
isolates do not differ genetically from carrier strains, in contrast to other studies that 
suggest disease is caused by hypervirulent clones (31, 120).  However, MLST 
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demonstrated that some STs are commonly found in high-risk patients, such as 
intravenous drug users, and these STs correlated with the disease presentation (73).  In 
depth analysis of the nature of mutations within alleles between members of a clonal 
group, demonstrated that S. aureus clonal diversification occurs 15-fold more frequently 
by point mutation than by recombination (31).   Similar fine-scale analyses indicate that 
methicillin-resistance in S. aureus may have been horizontally acquired at least 20 times 
and that these strains exist in five major lineages of S. aureus (17, 27, 113).   MLST 
demonstrated that the early MRSA isolates were highly related to MSSA isolates (28).   
Furthermore, modern MRSA lineages are unrelated by eBURST analysis to the early 
MRSA isolates further demonstrating that mecA has been acquired by horizontal transfer 
(92).  The horizontal acquisition of mecA into MSSA isolates has been corroborated by 
two separate studies that demonstrated that the first MRSA evolved from an epidemic 
MSSA isolate in Europe (20, 92).  A number of recent studies have attempted to use 
MLST to demonstrate the relationship between sporadic isolates, those occurring in one 
or a few patients, HA-MRSA, and CA-MRSA (2, 16).  As previously mentioned, these 
studies contradicted one another concerning the evolution of these epidemic clones from 
hospital-acquired strains (2, 16).  Three recent studies highlight the use of MLST in 
global epidemiology to track epidemic isolates; the identification of two major genotypes 
of MRSA in Asia with distinct geographic distributions (58), the introduction of epidemic 
ST239 in Saudi Arabia and Romania (15), and the first detection of an epidemic MRSA 
clone in Spain (87).   
 MLST using housekeeping genes has demonstrated use in defining clonal 
complexes  (40) and in global epidemiological applications but it is time consuming and 
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is not well suited for monitoring localized outbreaks.  The adaptation of the MLST 
protocol for use on the Light Cycler platform eliminates the need for electrophoresis and 
may diminish the processing time (6).  Similarly, the use of DNA array technology 
allows scanning of all genes of interest simultaneously which although time saving is at 
this time cost prohibitive (115).   Another variation of the technique is multilocus 
restriction fragment typing (MLRFT) in which housekeeping genes are amplified, 
digested, and visualized on an agarose gel.  This technique avoids the costs involved in 
sequencing but does not result in the genomic data necessary for the use of MLST in 
global studies.  While financial and technical factors may result in limited use of MLST 
for public health applications, further studies are 
needed to examine the possible use of virulence genes, in addition to housekeeping 
genes, to increase the discriminatory power for monitoring local outbreaks (17). 
 
Staphylococcal Protein A Gene Sequencing (spa Typing)  
 MLST has shown promise in studies of global epidemiology but the technique is 
time consuming due to the amplification and sequencing of seven genes for each isolate 
tested.  Therefore recent efforts have aimed at the use of single markers such as clumping 
factor B (clfB) typing, coagulase (coa) typing, and staphylococcal protein A (spa) gene 
typing for S. aureus subtyping (59, 60, 101).  The three techniques are similar in that each 
requires amplification and sequencing of repeat regions.  These studies have 
demonstrated that spa typing has the highest discriminatory power of the three genes, but 
it may also be used in combination with the other techniques for even higher resolution 
(59, 60, 101).     
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 The spa gene contains a polymorphic 24-base pair variable-number tandem repeat 
(VNTR) region, with unknown biological function, immediately upstream of the region 
coding the C-terminal cell wall attachment sequence (100).  The diversity of the repeat 
regions within spa is likely a result of deletion and duplication of the repetitive units and 
by point mutation (100).  Amplification and sequencing of spa is simplified by the 
existence of well-conserved regions flanking the repeats (83).  Repeats are easily located 
within a spa sequence by identifying the conserved regions.  The 24-base pair repeats can 
then be compared with known repeats using the online database 
(www.ridom.de/spaserver). The number of repeats and their order can then be used to 
determine the spa type using the spaserver.  Although the online server is currently free, 
an advanced database program, RidomStaphType®, is available that simplifies the 
technique by reading chromatograms directly from the sequencer and assigning spa types 
(41).   There is some disagreement on the acceptable length of spa repeats with one 
repeat reported as 21 base pairs long (53), but the database currently contains 96 reported 
repeats, most of which are 24 base pairs long.   Similarly, one study reported three of 41 
isolates were non-typeable by spa sequencing (1) while another successfully typed 
thousands of isolates (59).   Repeat combinations ranging from 1 repeat per isolate to 23 
repeats in one isolate are represented in the online database resulting in the designation of 
1165 spa types from 21 countries to date (www.ridom.de/spaserver).  The assignment of 
simple numeric codes, use of just one gene for amplification and sequencing, 
standardization of the protocols among laboratories, and the ease of data storage 
illustrates some of the advantages of using simple PCR-based approaches such as spa 
typing (100, 106).  However, studies using this technique have found that while strains 
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with different spa types can generally be considered not related, strains with the same spa 
type are not necessarily epidemiologically related (106).     
 Several recent studies have correlated spa type 44 with CA-MRSA isolates that 
are PVL positive recovered from infections in Denmark (30), Belgium (22), and 
Germany, France, and Switzerland (121).  In a German hospital, spa typing was 
successfully used to track epidemic isolates and to disprove that person-to-person 
transmission of MRSA was occurring within the facility which allowed better use of 
infection control resources (41).  A comparison of HA-MRSA with HA-MSSA and CA-
MSSA in Portugal using spa typing found that the three major MRSA clones were not 
related to any of the MSSA isolates tested (1).  This data suggests that MRSA in Portugal 
did not result from acquisition of SCCmec by MSSA isolates in Portugal but likely was 
imported from abroad (1).  A study of isolates in Hungary demonstrated that MRSA 
isolates recently introduced into the hospital environment varied little in spa types but 
MRSA clones circulating for longer periods of time and spread among several hospitals 
showed a higher degree of variability (83).  This study further suggests that the spa gene 
may play a role in attachment and pathogenesis as an explanation for why certain 
epidemic clones, with stable spa types, are highly successful and have been circulating 
for decades (83).  The comparison of CA-MRSA isolates to HA-MRSA isolates 
suggested once again that CA-MRSA is the result of recent acquisition of SCCmec into a 
MSSA background because all CA-MRSA isolates were related by spa typing but none 
were related to the HA-MRSA isolates (34).   Some studies suggest that spa is relatively 
stable and can therefore be used to characterize both macro- and microevolution in the 
primarily clonal population structure of S. aureus (59, 100).  However, a recent study of 
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S. aureus isolates recovered from persistently infected cystic fibrosis patients found that 
one genetic change occurs in spa every 70 months (53).  While some of the problems 
encountered with the use of spa gene typing, including low discriminatory power, may be 
overcome by combining the techniques such as coa typing and hypervariable region 
typing (74, 103), the expense of sequencing will continue to restrict the use of 
PCR/sequence based typing methods.              
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Objectives 
 Recent studies have demonstrated the emergence of highly virulent community-
acquired isolates of S. aureus that are capable of causing serious disease in otherwise 
healthy populations.  These infections are of concern due to increased morbidity, 
mortality, and cost of care.  Surveillance programs should be implemented by public 
health, hospital, and research laboratories to determine the extent of CA-MRSA 
dissemination, to better understand the epidemiology behind the spread of the organism, 
to propose infection control measures, and to provide adequate treatment.  Currently there 
is no ongoing surveillance of S. aureus infections in the United States and the objective 
of this project was to determine what typing methods would be suitable for monitoring S. 
aureus.  The suspected outcome is that no one typing method will be suitable for each S. 
aureus typing study and that the method should be selected based on the desired 
outcome.    The following specific aims were designed to test this hypothesis: 
 
1. To establish a database of S. aureus isolates and categorize the isolates by PFGE. 
2. To type a subset of the S. aureus isolates using MLST. 
3. To type the same subset of S. aureus isolates using spa Typing. 
4. To compare and contrast the usefulness of the 3 typing methods for public health 
applications. 
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Materials and Methods 
S. aureus Isolates 
 A total of 403 isolates were used in this study, including community-
associated methicillin-resistant S. aureus (CA-MRSA) organisms isolated from wound, 
nose, sputum, blood, and other sources.  CA-MRSA isolates were requested from two 
hospitals in Washington, 1 hospital in Florida, and Quest Diagnostics, a regional testing 
laboratory in Florida.  All clinical isolates were collected from patients treated on an 
outpatient basis, within 48 hours of consultation.  Control strains USA 100 – USA 800 
were obtained from the Network on Antimicrobial Resistance in S. aureus (NARSA) 
(Table 3).  The PFGE standardization control strain, NCTC 8324 (NRS77) was also 
obtained from NARSA.  Several additional strains were obtained from the American 
Type Tissue Collection (ATCC) (Manassas, VA) (Table 3).  The identification of all 
isolates as methicillin-resistant S. aureus was based on Gram stain reaction and cell 
morphology, catalase reaction, Microdase disk oxidase test (REMEL Inc., Lenexa, KS), 
slide and tube coagulase testing in rabbit plasma with EDTA (REMEL Inc.) and the API 
STAPH® identification system (bioMerieux, Inc., Hazelwood, MO) supplemented with 
lysostaphin testing (REMEL Inc.).  Profiles were analyzed using the API STAPH® 
Codebook, Reference # 20590, 14th Edition.  Methicillin-resistance was determined on 
Mueller Hinton agar by the direct colony method of standardized disk diffusion 
susceptibility testing against 1 μg oxacillin and 30 μg cefoxitin disks incubated at 35°C 
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and 30°C, respectively (REMEL Inc., Technical Insert No. 33000) (49).  Zones of 
inhibition <10mm around the oxacillin disk and  <19 mm at cefoxitin are indicative of 
oxacillin and methicillin resistance (9).  The presence of the mecA gene product was 
confirmed using the Penicillin Binding Protein (PBP2’) Latex Agglutination Test (Oxoid 
Limited, Hampshire, England).  A list of all strains used in the study appears in Appendix 
A.  
 
TABLE 3. Control strains  
CBD Designation Identifier 
CBD0007 ATCC 14458A 
CBD0019 ATCC 51740 
CBD0034 ATCC 29213 
CBD0036 ATCC 14458B 
   CBD 0044 ATCC 25923 
CBD0544 ATCC 6538 
CBD0545 ATCC 12600 
CBD0623 NRS77 (NCTC 8325) 
CBD0653 ATCC 33593 
CBD0654 NRS 100 (COL) 
CBD0655 NRS 271A 
CBD0656 NRS 271B 
CBD0797 NRS 70 (N315) 
CBD0798 NRS 123 
CBD0835 ATCC 49775A 
CBD0836 ATCC 49775B 
CBD1064 NRS382 (USA 100) 
CBD1065 NRS383 (USA 200) 
CBD1066 NRS384 (USA 300) 
CBD1067 NRS123 (USA 400) 
CBD1068 NRS385 (USA 500) 
CBD1069 NRS22 (USA 600) 
CBD1070 NRS386 (USA 700) 
CBD1071 NRS387 (USA 800) 
 
Pulsed-field Gel Electrophoresis 
 A single isolated colony of S. aureus was aseptically transferred from a BBLTM 
Trypicase Soy Agar Plate (Becton Dickinson, Sparks, MD) to 5 ml BBLTM TrypticaseTM 
Soy Broth (Becton Dickinson, Sparks, MD).  The broth culture was incubated 16 hours in 
25 
a 37°C water bath with gentle agitation.  Cells were pelleted for 10 min at 4°C, 5200 g 
and resuspended in 1.5 ml of PIV solution (10 mM Tris-HCl, 1 M NaCl).  Plugs were 
prepared by adding 300 μl of cells to 300 μl of InCert agarose (Cambrex Bioscience, 
Rockland, ME),  
pipeting the mixture into reusable plug molds (Bio-Rad, Hercules, CA), and allowing 
them to cool for 10 min at 4°C.    The plugs were then incubated for 5 hr at 37°C in 7 ml 
of EC-Lysis solution (6 mM Tris-HCl (pH 7.6), 1 M NaCl, 100 mM EDTA (pH 7.5), 
0.5% Brij-58, 0.2% Deoxycholate, 0.5% sarkosyl, 20 μg/ml RNase, 1 mg/ml lysozyme).   
Lysostaphin (no. L7386, Sigma, St. Louis, MO) was added to the EC-Lysis buffer at a 
concentration of 3 U/ml.  EC-lysis solution was replaced with ESP solution (0.5 M 
EDTA (pH 9.0), 1% sarkosyl, 50 μg/ml proteinase K) and the plugs were incubated 
overnight at 50°C.  Plugs were then washed three times (45 min each wash) with TE (10 
mM Tris-HCl (pH 7.5)), 1 mM EDTA (pH 7.5) and stored at 4°C until needed.   
Plugs were digested in SmaI overnight at room temperature (or overnight at 37°C 
for EagI and SacII digestions).  Plugs were then melted at 69°C for 10 min, and loaded 
into the wells of a 1.6% Seakem Gold (Cambrex BioScience, Rockland, ME) gel 
prepared by adding 3.2 g of agarose to 200 ml of 0.5X TBE (Tris – Boric Acid – EDTA).  
SmaI digested NCTC 8325 was used as a marker for all gels.  PFGE was performed using 
a DR-II CHEF Mapper (Bio-Rad, Hercules, CA) using the following parameters: 200V, 
14°C, 5.3 s initial switch, 34.9 s final switch, 0.5X TBE running buffer, and 20 to 22 hrs 
run time. The run time varied based on which of two available DR-II CHEF Mapper gel 
boxes was utilized.  Following electrophoresis, gels were stained for 20 min in 200 ml of 
water containing 1 μg/ml ethidium bromide and destained for 20 min in water (repeat 
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2x).  Gels were then visualized using the Bio-Rad Gel Doc System utilizing the Quantity 
One version 4.6 software (Bio-Rad, Hercules, CA).  Data was analyzed using 
BioNumerics® (Applied Math, Sint-Martens, Belgium) Version 3.0.  Dendrograms were 
derived from the unweighted pair group method using arithmetic averages (UPGMA) and 
based on Dice coefficients.  Band position tolerance and optimization were set at 1.00%.   
 
Virtual Digestion to Identify Secondary Enzymes for S. aureus PFGE 
 A list of 262 commercially available enzymes was compiled using catalog lists 
from New England Biolabs (Beverly, MA), Fisher Scientific (Pittsburgh, PA) Roche 
Applied Science (Indianapolis, IN), and Invitrogen (Carlsbad, CA).  A list of all enzymes 
tested appears in Table 7.  Restriction digestion of the S. aureus MW2 genome was 
performed for all 262 enzymes online at The Institute for Genomic Research (TIGR) 
website using the Restriction Digest Tool (www.tigr.org/tigr-
scripts/CMR2/restrict_display.pl).  Using a subset of the enzymes, the genomes of other 
available S. aureus genomes including, Staphylococcus aureus Michigan VRSA and 
Staphylococcus aureus MU50 were digested.  This resulted in the same size fragments 
for the S. aureus MW2 genome thus it was determined that virtual digestion of the MW2 
genome was sufficient.  Only those enzymes that resulted in 10 to 50 fragments were 
further considered for S. aureus PFGE.   
 
DNA Isolation for MLST and spa Typing   
 Genomic DNA was isolated from all S. aureus strains using the MagNA Pure LC 
DNA Isolation Kit III (Bacteria, Fungi) (Roche Diagnostics, Indianapolis, IN) protocol as 
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follows.  Cells were grown for 16 hours at 37°C in 4 ml BBLTM TrypticaseTM Soy Broth 
(Becton Dickinson, Sparks, MD).  Pellets were obtained by centrifugation of 1 ml of the 
overnight cell culture at 8,000 g for 10 min.  After discarding the supernatant, the 
samples were lysed by adding 130 μl of Bacterial Lysis Buffer, followed by mixing, then 
adding 20 μl of Proteinase K provided in the kit and incubation for 10 min at 65°C.  
Organisms were then inactivated by boiling samples at 95°C for 10 min.  Magnetic glass 
particles, which bind to the DNA, were added to the samples immediately before loaded 
onto the MagNA Pure LC Instrument (Roche Diagnostics, Indianapolis, IN).  Samples 
were loading following onscreen instructions and the instrument performed a series of 
washes that removed unbound substances.  The DNA was then eluted and it was 
experimentally determined through a series of dilutions that 1:20 dilutions of MagNA 
Pure genomic DNA sample was sufficient as template for both MLST and spa typing 
polymerase chain reactions.  
 
PCR for Multilocus Sequence Typing  
 MLST of 30 S. aureus isolates was performed as per the standardized protocol 
(http://saureus.mlst.net/misc/info.asp).  Internal fragments of the following seven house-
keeping genes; arc (carbamate kinase), aro (shikimate dehydrogenase), glp (glycerol 
kinase), gmk (guanylate kinase), pta (phosphate acetyltransferase), tpi (triosephosphate 
isomerase), yqi (acetyl coenzyme A acetyltransferase) were amplified by PCR.  PCR 
master mixes were prepared for each amplification using reagents from the Takara PCR 
Amplification Kit (Fisher Scientific, Pittsburg, PA) including 6µl MgCl2, 5 µl 10x PCR 
buffer, and 4 µl dNTPs.  Each reaction included 1 µl each forward and reverse primers (1 
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μg/µl), 0.25 µl (1.2U) Takara Taq polymerase (Fisher Scientific, Pittsburg, PA), and 30 
µl water for each reaction.  Approximately 3µl of 1:20 MagNA Pure isolated genomic 
DNA was added as template. The PCR protocol included an initial 5 min denaturation at 
95°C, followed by 30 cycles of denaturation at 95°C for 1 min, annealing at 55° C for 1 
min, extension at 72°C for 1 min, and a final extension step of 72°C for 5 min.  The 
annealing temperature was raised to 65°C for PCR amplification of the gmk, pta, and/or 
yqi gene for some isolates to obtain a single band.  A list of all primers used for MLST 
PCR appears in Table 4.   
 
PCR for spa Typing 
 Amplification of the spa gene was performed for 30 S. aureus isolates using the 
same master mix, DNA concentration, and primer concentration as reported above for 
MLST.   The primers used for spa are listed in Table 4.  Isolates CBD0614 and CBD0633 
required the use of spaF2 (spa Forward 2) primer, all other isolates were amplified with 
spaF1.  The PCR protocol included an initial 10 min denaturation at 95°C, followed by 
30 cycles of 30 seconds denaturation at 95°C, annealing at 60°C for 30 sec, extension at 
72°C for 45 sec, and a final extension step of 72°C for 10 min (83).   
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TABLE 4. MLST and spa typing primers – primer sequences 
obtained from www.mlst.net and www.ridom.de/spaserver/. 
Primer Designation Sequence (5’ to 3’) 
arc Forward TTG ATT CAC CAG CGC GTA TTG TC 
arc Reverse AGG TAT CTG CTT CAA TCA GCG 
aro Forward ATC GGA AAT CCT ATT TCA CAT TC 
aro Reverse GGT GTT GTA TTA ATA ACG ATA TC 
   glp Forward CTA GGA ACT GCA ATC TTA ATC C 
glp Reverse TGG TAA AAT CGC ATG TCC AAT TC 
gmk Forward ATC GTT TTA TCG GGA CCA TC 
gmk Reverse TCA TTA ACT ACA ACG TAA TCG TA 
pta Forward GTT AAA ATC GTA TTA CCT GAA GG 
pta Reverse GAC CCT TTT GTT GAA AAG CTT AA 
tpi Forward TCG TTC ATT CTG AAC GTC GTG AA 
tpi Reverse TTT GCA CCT TCT AAC AAT TGT AC 
yqi Forward CAG CAT ACA GGA CAC CTA TTG GC 
yqi Reverse CGT TGA GGA ATC GAT ACT GGA AC 
spaF1 (Forward 1) GAC GAT CCT TCG GTG AGC 
spaF2 (Forward 2) CAG CAG TAG TGC CGT TTG C 
spa Reverse GAA CAA CGT AAC GGC TTC ATC C 
 
Wizard® PCR Clean-up Kit for MLST and spa Typing 
PCR products were purified (removal of amplification primers and primer dimers) 
for sequencing using the Wizard® PCR Preps DNA Purification System (Promega, 
Madison, WI) as follows.  100µl of Direct PCR Purification Buffer was added to the PCR 
product followed by mixing.  The DNA was then added to 1 ml of resin and vortexed 
briefly 3 times over a 1 min interval to bind the DNA to the resin.  The DNA/resin 
mixture was then transferred to a 3 ml syringe with a Wizard® Minicolumn attached.  The 
syringe was then used to push the resin/DNA slurry into the minicolumn.  A wash step 
was performed by adding 2 ml 80% isopropanol to the syringe and pushing it through the 
minicolumn.  The minicolumn was then transferred to a 1.5 ml microcentrifuge tube 
followed by centrifugation at 10,000 g for 2 min.  The minicolumn was then transferred 
to a second 1.5 ml microcentrifuge tube.  To elute the DNA, 30 µl of 65°C water was 
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added to the column and allowed to stand 1 min.   Centrifugation for 1 min eluted the 
DNA which was then stored at 
-20°C until needed.   
 
Preparation of DNA Sequencing Reactions for MLST and spa Typing 
 All sequencing reactions were performed on a CEQ 8000 Sequencer (Beckman 
Coulter, Fullerton, CA) using the CEQ Dye Terminator Cycle Sequencing with Quick 
Start Kit (Beckman Coulter, Fullerton, CA) as follows.  Sequencing reactions were 
performed in 0.2 ml tubes containing 8.0 μL DTCS Quick Start Master Mix, 2.0 μL 
primer (25 pmol/μL), 2 μL template, and 8.0 μL of water.  The recommended thermal 
cycling program was 30 cycles of 96°C for 20 sec, 50°C for 20 sec, and 60°C for 4 min.  
Ethanol precipitation of all templates was then performed as follows.  The templates were 
added to sterile 0.5 ml microfuge tubes and 4 μL of stop solution (equal volumes of 1.5 
M NaOAc (pH 5.2) and 50 mM EDTA (pH 8.0) and 1 μL of glycogen (20 mg/ml) was 
added.  Following a brief mix, 60 μL of cold 95% ethanol was added to each template 
and mixed.  The samples were then centrifuged at the maximum speed for 15 min at 4°C.  
The supernatants were then removed without disturbing the pellets.  The pellets were then 
washed with 200 μL of cold 70% ethanol and centrifuged at maximum speed for 10 min 
at 4°C.  The wash step was then repeated and the pellets were dried in a concentrator for 
20 min.  Dried pellets were resuspended in 40 μL of sample loading solution and 
transferred to a 96-well sequencing plate (Beckman-Coulter, Fullerton, CA).  A drop of 
mineral oil was added to each sample before loading onto the CEQ 8000 and running the 
LFR (Long Fragment Run) sequencing program.  All sequences were aligned using the 
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SeqMan II component of the Lasergene Expert Sequence Analysis Software package 
(DNASTAR, Madison, WI).  MLST alleles and sequence types were assigned using 
online MLST database (http://saureus.mlst.net).  All spa typing alleles and spa types 
were assigned using the online database (http://spa.ridom.de/spatypes.shtml).  
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Results 
Staphylococcus aureus BioNumerics® Database 
 PulseNet has demonstrated that PFGE is useful for tracking trends in the spread of 
microorganisms of interest.  A large collection of S. aureus isolates including clinical 
isolates from Florida and Washington was used to develop a database of DNA fingerprint 
patterns that could be used to investigate the trends of S. aureus infection in these two 
states.  Macrorestriction followed by pulsed-field gel electrophoresis was performed for 
every S. aureus isolate in the Center for Biological Defense (CBD) collection.  The S. 
aureus PFGE size standard, SmaI digested NRS77 (NCTC 8325), was used for 
normalization.  This standard is required by the software to allow comparison across the 
length of the agarose gels and to allow gel to gel comparison.  The standard was run in 
lanes 1, 6, 11 and 15 on gels prepared with a small comb (15 wells), and in lanes 1, 5, and 
10 on gels prepared with a larger comb (10 wells) (Figure 1).  PFGE was performed on a 
total of 403 isolates and all isolates were typeable by this technique.  Images from a total 
of 44 gels were imported into the BioNumerics® database and a UPGMA dendrogram 
based on Dice coefficients was generated.   
A total of 88 isolates matched the USA 100 pulsotype and 136 isolates matched 
the USA 300 pulsotype.  The remaining 161 isolates (does not include non-epidemic 
control strains) demonstrated pulsotypes consistent with sporadic strains as the patterns 
were either unique to that strain or were present in a low number of isolates.  A 
dendrogram was generated using BioNumerics® to represent all of the strains included in 
the study (Figure 2).  In this figure, USA 100 and USA 300 epidemic clone control 
strains represent 88 and 136 isolates respectively (Figure 2).  Data for each individual 
strain is included in Appendix A.   
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Figure 1.  Pulsed-field gel electrophoresis of Staphylococcus aureus.  S. aureus 
isolates were run on 1.0% agarose gels following macrorestriction with SmaI enzyme.  
The standard marker (NCTC 8325) was run in lanes 1, 5, and 10 to allow normalization 
across the gel as well as gel to gel comparison.  Images were uploaded to the 
BioNumerics® software package for dendrogram creation.   
 
  
 
Figure 2.  Dendrogram of sporadic isolates and epidemic controls.  Data was 
analyzed using BioNumerics® (Applied Math, Sint-Martens, Belgium) Version 3.0.  
Dendrograms were derived from the unweighted pair group method using arithmetic 
averages (UPGMA) and based on Dice coefficients.  Band position tolerance and 
optimization were set at 1.00%. 
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Figure 2. (Continued)  Dendrogram of sporadic isolates and epidemic 
controls.  
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Figure 2. (Continued)  Dendrogram of sporadic isolates and epidemic 
controls. 
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Figure 2. (Continued)  Dendrogram of sporadic isolates and epidemic 
controls.  
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Analysis of S. aureus Epidemic Clone USA 300 in S. aureus PFGE Database.   
 A number of studies have demonstrated the epidemiology of this strain and its 
link to wound infections and necrotizing pneumonia (12, 37, 71).  The dendrogram 
generated by BioNumerics® analysis indicated that a large number of isolates possessed 
pulsotypes consistent with the USA 300 epidemic clone control strain.  This analysis 
demonstrated the first documented USA 300 isolates in both Florida and Washington 
State.  Excluding those isolates from unknown sources, non-clinical sources, unknown 
clinical background, and/or non-MRSA, the database contains 332 CA-MRSA clinical 
isolates.  A total of 136 CA-MRSA isolates were found to possess pulsotypes consistent 
with the USA 300 clone including 119 isolates from Florida and 17 isolates from 
Washington.  Although the clinical background of these isolates was limited, they were 
grouped according to their source, i.e. wound, sputum, blood, nose, and other.  Isolates 
that were reported as abscess, wound, furunculosis, and cellulitis were grouped as wound 
infections, while those listed as nasal, nose, and nares were grouped as nose infections.  
Clinical sources listed as other included urine, unspecified body fluid, eye, feces, and 
cervix.  The clinical source for each individual isolate is listed in Appendix 1.  Wound 
infections accounted for the majority of the 332 clinical isolates in the database, 194 
(58%) of the isolates.  A total of 121 of these wound isolates (63%) demonstrated the 
USA 300 pulsotype (Table 5).  These data demonstrated both that the majority of isolates 
in the database are from wounds and that the majority of the wound isolates are USA 300 
pulsotype.  Although USA 300 was present in isolates from the other clinical sources, it 
constituted a minority of the isolates (Table 5).  
  
TABLE 5.  Summary of results for all isolates tested 
No. (%) of isolates: 
USA 300 positive USA 300 negative 
Source 
of 
Isolates FL WA FL WA 
Total no. of 
isolates 
from source (% of 
total) 
Wound 106 (55) 15 (8) 63 (32) 10 (5) 194 (58) 
Sputum 1 (6) 0 8 (50) 7 (44) 16 (5) 
Blood 1 (5) 1 (5) 15 (71) 4 (19) 21 (6) 
Nose 10 (11) 1 (1) 76 (87) 0 87 (26) 
Other 1 (7) 0 12 (86) 1 (7) 14 (4) 
      
Total 119 (36) 17 (5) 174 (52) 22 (7) 332 (100) 
 
 
 
Analysis of S. aureus Epidemic Clone USA 100 in S. aureus PFGE Database. 
 There is a paucity of data concerning the epidemiology of the USA 100 epidemic 
clone but it is believed to be primary an HA-MRSA (70).  Analysis of the S. aureus 
BioNumerics® database demonstrated that 88 of the isolates have pulsotypes consistent 
with USA 100 (no more than 1 band difference).  Using the same exclusion criteria as the 
USA 300 analysis, the database containing CA-MRSA isolates includes 82 USA 100 
isolates from Florida and 6 USA 100 isolates from Washington State.  USA 100 isolates 
constituted the majority of the nose (47%) and blood (58%) isolates and was rarely 
present in wound, sputum, and isolates from other clinical sources (Table 6).  The clinical 
source for each individual isolate is listed in Appendix 1.  Few blood isolates were 
present in the database (21 total), limiting the conclusions that can be made concerning 
the etiology of blood-borne infections caused by this clone.  However, S. aureus was 
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identified in 87 nose isolates confirming the nose as the second most common isolation 
site behind wound isolates (Table 6).  Due to the limited clinical information provided for 
the isolates in this study, it is unclear whether these nose isolates were a cause of 
infection or if they are present as colonizing strains.      
 
TABLE 6.  Summary of results for all isolates tested 
No. (%) of isolates: 
USA 100 positive USA 100 negative 
Source of 
Isolates 
FL WA FL WA 
Total no. of isolates
from source (% of 
total) 
Wound 25 (13) 1 (1) 144 (74) 24 (12) 194 (58) 
Sputum 0  3 (19) 9 (56) 4 (25) 16 (5) 
Blood 10 (48) 2 (10) 6 (29) 3 (14) 21 (6) 
Nose 41 (47) 0 45(52) 1 (1) 87 (26) 
Other 6 (43) 0 7 (50) 1 (7) 14 (4) 
      
Total 82 (25) 6 (2) 211 (64) 33 (10) 332 (100) 
 
 
 
Use of Restriction Digestion of the MW2 Genome to Identify Secondary Enzymes 
for S. aureus PFGE.   
Studies with organisms other than S. aureus have demonstrated that differences in 
strains are often not detected by the use of just one restriction enzyme for PFGE (88).  
Virtual digestion of the S. aureus enzyme was performed in an attempt to find a 
secondary enzyme for S. aureus PFGE.  A total of 262 commercially available restriction 
enzymes were tested for their ability to virtually digest the MW2 S. aureus genome into 
10 to 50 fragments.  Restriction digestion was performed using the TIGR Restriction 
Digest Tool (www.tigr.org/tigr-scripts/CMR2/restrict_display.pl) and the S. aureus 
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MW2, Michigan VRSA, and MU50 genomes.  After testing 25 enzymes it was 
determined that the same number of restriction fragments resulted regardless of the S. 
aureus genome selected and further digestions used only the S. aureus MW2 genome.  
The majority of the enzymes, 242, resulted in >50 fragments which cannot be resolved on 
a conventional pulsed-field gel.  Eleven enzymes either failed to cut or had recognition 
sites in the S. aureus MW2 genome that would result in too few bands for 
epidemiological studies.  Two enzymes were excluded based on expense as their use 
would exceed $1,000 per gel.  Two additional enzymes were excluded because the 
resulting digestion pattern would contain bands that are too close together to be resolved 
by PFGE.  This technique also identified XmaI and XmaCI, both of which are 
isoschizomers of SmaI.   Because their use would result in the same pattern as SmaI and 
since SmaI is less expensive and in common use, these two enzymes were also excluded.  
Results for each enzyme tested are shown in Table 7.  Virtual digestion and application of 
the criteria mentioned above resulted in the identification of two enzymes, in addition to 
SmaI, EagI and SacII, which could potentially be used for S. aureus PFGE.   
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 Enzyme Fragments  Enzyme Fragments  Enzyme Fragments
1 Aat II  82 37 Ban II  0 73 BsmB I  168 
2 Acc I  1250 38 BbrP I  412 74 BsmF I  479 
3 Acc III  122 39 Bbs I  491 75 BsoB I  163 
4 Acc B7 I  441 40 Bbv I  1561 76 Bsp12861  1178 
5 Acc65 I  166 41 BbvC I  36 77 BspD I  1047 
6 Aci I  2144 42 Bcc I  2239 78 BspE I  122 
7 Acl I  1227 43 Bcg I  249 79 BspH I  1073 
8 Acs I  8109 44 BciV I  319 80 BspM I  535 
9 Acy I  541 45 Bcl I  1007 81 BspLU11 I  864 
10 Afe I  259 46 Bfa I  4374 82 Bsr I  1499 
11 Afl II  356 47 Bfr I  356 83 BsrB I  64 
12 Afl III  2059 48 BfrB I  1367 84 BsrD I  904 
13 Age I  169 49 Bgl II  162 85 BsrF I  482 
14 Ahd I  167 50 Blp I  216 86 BsrG I  758 
15 Alu I  8998 51 Bmr I  178 87 BsrS I  1499 
16 Alw26 I  824 53 Bmy I  1178 88 BssH II  74 
17 Alw44 I  355 53 Bpm I  183 89 BssK I  1792 
18 Alw I  966 54 BpuA I  491 90 BssS I  179 
19 AlwN I  546 55 Bpu10 I  184 91 Bst1 107 I  547 
20 Apa I  115 56 Bsa I  106 92 BstAP I  897 
21 ApaL I  355 57 BsaA I   1897 93 BstB I  807 
22 Apo I  8109 58 BsaB I  1113 94 BstE II  213 
23 Asc I  5 59 BsaH I  541 95 BstF5 I  1429 
24 Ase I  4484 60 BsaJ I  1371 96 BstN I  1471 
25 Asp700  1060 61 BsaM I  502 97 BstO I  1471 
26 Asp718  166 62 BsaW I  561 98 BstU I  1796 
27 AspE I  167 63 BsaX I  199 99 BstX I  298 
28 AspH I  766 64 BseR I  155 100 BstY I  799 
29 Asp I  231 65 Bsg I  425 101 BstZ17 I  547 
30 Ava I  163 66 BsiE I  295 102 Bst98 I  356 
31 Ava II  1242 67 BsiHKA I  766 103 Bsu36 I  110 
32 Avr II  95 68 BsiW I  180 104 Btg I  436 
33 Bae I  283 69 BsiY I  200 105 Bts I  261 
34 Bal I  269 70 Bsl I  30 106 Cac8 I  2633 
35 BamHI  115 71 Bsm I   502 107 Cel II  216 
36 Ban I  642 72 BsmA I  824 108 Cfo I  3175 
 
 
Table 7.  Virtual digestion of S. aureus MW2 genome.  A total of 262 enzymes were 
used to virtually digest the S. aureus genome.  The resulting fragment numbers are listed 
in the table.  Isolates with digestion results of 10 to 50 fragments (bold) were considered 
for further analysis.  
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 Enzyme Fragments  Enzyme Fragments  Enzyme Fragments
109 Cfr10 I  482 145 HinF I  7098 181 Mvn I  1796 
110 Cla I  1047 146 Hpa I  755 182 Mwo I  1250 
111 Csp I  12 147 Hpa II  1331 183 Nae I  59 
112 Csp45 I  807 148 Hph I  2163 184 Nar I  77 
113 CviA II  9004 149 Hpy99 I  1423 185 Nci I  320 
114 Dde I  4962 150 Hpy188 I  6130 186 Nco I  238 
115 Dpn I  5167 151 HpyCH4 III  7180 187 Nde I  1173 
116 Dpn II  5167 152 HpyCH4 IV  8749 188 Nde II  5167 
117 Dra I  5616 153 HpyCH4 V  13916 189 NgoM IV  59 
118 Dra II  466 154 Hsp92 I  541 190 Nhe I  201 
119 Dra III  358 155 Hsp92 II  9004 191 Nla III  161 
120 Drd I  229 156 Ita I  3972 192 Nla IV  1685 
121 Eae I  477 157 Kas I  77 193 Not I  0 
122 Eag I  27 158 Kpn I  166 194 Nru I  165 
123 Ear I  420 159 Ksp I  28 195 Nsi I  1367 
124 Eci I  145 160 Ksp632 I  420 196 Nsp I  2181 
125 Ecl HK I  167 161 Mae I  4374 197 Pac I  429 
126 EclX I  27 162 Mae II  8749 198 PaeR7 I  75 
127 Eco47 III  256 163 Mae III  7993 199 Pci I  864 
128 Eco52 I  27 164 Mam I  1113 200 PfiF I  231 
129 EcoN I  243 186 Mbo I  5167 201 PflM I  441 
130 EcoO109 I  466 166 Mbo II  4292 202 PinA I  165 
131 EcoR I  625 167 Mfe I  2044 203 Ple I   760 
132 EcoR II  1471 168 Mlu I  220 204 Pme I  76 
133 EcoR V  917 169 MluN I  269 205 Pml I  412 
134 Fau I  303 170 Mly I  760 206 PpuM I  225 
135 Fnu4H I  3972 171 Mme I  769 207 PshA I  151 
136 Fok I  1429 172 Mnl I  3100 208 Psi I  2673 
137 Fse I  0 173 Mro I  122 209 Psp1406 I  1227 
138 Fsp I  364 174 Msc I  269 210 PspG I  1471 
139 Hae II  829 175 Mse I  36832 211 PspOM I  115 
140 Hae III  1362 176 Msl I  2441 212 Pst I  453 
141 Hga I  768 177 Msp I  1331 213 Pvu I  90 
142 Hha I  3175 178 MspA1 I  815 214 Pvu II  598 
143 Hinc II  1846 179 Mun I  2044 215 Rca I  1073 
144 Hind III  1069 180 Mva I  1471 216 Rsa I  7280 
 
 
Table 7 (Continued).  Virtual digestion of S. aureus MW2 genome.  A total of 262 
enzymes were used to virtually digest the S. aureus genome.  The resulting fragment 
numbers are listed in the table.  Isolates with digestion results of 10 to 50 fragments 
(bold) were considered for further analysis.  
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 Enzyme Fragments  Enzyme Fragments  Enzyme Fragments
217 Rsr II  12 233 SgF I  4 249 Tse I  3171 
218 Sac I  62 234 SgrA I  13 250 Tsp45 I  2783 
219 Sac II  28 235 Sma I  27 251 Tsp509 I  37578 
220 Sal I  149 236 Sml I  1276 251 TspR I  2461 
221 Sap I  85 237 SnaB I  625 253 Tth111 I  231 
222 Sau3A I  5167 238 Spe I  385 254 Van91 I  441 
223 Sau96 I  1801 239 Sph I  280 255 Vsp I  4484 
224 Sbf I  11 240 Ssp I  4198 256 Xba I  400 
225 Sca I  534 241 SspB I  758 257 Xcm I  5000 
226 ScrF I  1792 242 Stu I  82 258 Xho I  75 
227 SexA I  358 243 Sty I  745 259 Xho II  799 
228 SfaN I  2554 244 Swa I  584 260 Xma I  27 
229 Sfc I  1925 245 Taq I  6741 261 XmaC I  27 
230 Sfi I  0 246 Tfi I  5494 262 Xmn I  1060 
231 Sfo I  77 247 Tli I  75    
232 Sfu I  807 248 Tru9 I  36832    
 
Table 7 (Continued).  Virtual digestion of S. aureus MW2 genome.  A total of 262 
enzymes were used to virtually digest the S. aureus genome.  The resulting fragment 
numbers are listed in the table.  Isolates with digestion results of 10 to 50 fragments 
(bold) were considered for further analysis.  
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Analysis of the PFGE Patterns of 12 USA 300 Epidemic Clone Isolates Using SmaI, 
EagI, and SacII.    
Twelve CA-MRSA isolates that have identical SmaI pulsotypes consistent with 
the USA 300 epidemic clone were used to test the ability of the two additional enzymes 
to discriminate identical isolates (Figure 3).  Restriction digestion of these isolates with 
EagI resulted in approximately the same number of fragments as digestion with SmaI, 
although the pulsotype generated was distinct from that of SmaI (Figure 4).  Phylogenetic 
analysis of the EagI PFGE using the BioNumerics® software package determined that 
the 12 isolates were identical.  Likewise, digestion with SacII resulted in a unique 
pulsotype, but with approximately the same number of bands as the other two enzymes 
(Figure 5).  As shown in Figure 5, digestion with SacII also confirmed that the 12 CA-
MRSA USA 300 isolates are identical.  Thus, S. aureus PFGE was successfully 
performed with the three enzymes predicted by virtual digestion and BioNumerics® 
analysis of the three pulsed-field gels was in agreement that the 12 isolates are 100% 
identical.    
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Figure 3. USA 300 isolates demonstrating 100% identity by SmaI PFGE.  Isolates 
possessing pulsotypes identical to the USA 300 epidemic clone were used to demonstrate 
the use of SmaI for digestion for PFGE.  The original clinical source information is 
present in the figure.  Quest represents isolates obtained from Quest Diagnostics in 
Tampa, Florida.  
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Figure 4. USA 300 isolates demonstrating 100% identity by EagI PFGE.  The same 
isolates present in Figure 3 were used to demonstrate the use of EagI for digestion of  
S. aureus for PFGE.  The original clinical source information is present in the figure.  
Quest represents isolates obtained from Quest Diagnostics and TGH isolates obtained 
from Tampa General Hospital both in Tampa, Florida. 
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Figure 5. USA 300 isolates demonstrating 100% identity by SacII PFGE.  The same 
isolates present in Figure 3 were used to demonstrate the use of SacII for digestion of  
S. aureus for PFGE.  The original clinical source information is present in the figure.  
Quest represents isolates obtained from Quest Diagnostics and TGH isolates obtained 
from Tampa General Hospital both in Tampa, Florida. 
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Analysis of the PFGE Patterns of Seven Pairs of Identical Isolates using SmaI, EagI, 
and SacII.     
Seven pairs of CA-MRSA isolates that were 100% identical by SmaI PFGE 
(Figure 6) were chosen to test the ability of EagI and SacII to further discriminate the 
pairs.  Digestion with both enzymes again resulted in approximately the same number of 
resolvable fragments as SmaI as predicted by virtual digestion.  However, digestion with 
EagI and subsequent BioNumerics® analysis demonstrated one to two band differences 
between isolates within three of the seven pairs (Figures 7).  Similarly, digestion with 
SacII followed by BioNumerics analysis also detected one to two band differences 
between isolates in the same three pairs as identified using EagI (Figure 7 and 8).    Thus, 
EagI and SacII were able to discriminate between isolates that were identical by SmaI 
(Figures 6-8).   
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Figure 6.  Seven pairs of identical isolates by SmaI PFGE.   SmaI digestion was used 
to demonstrate seven pairs of identical isolates.  The original source of the isolates is 
shown.  The NRS100 control strain, obtained from NARSA, is included in this set of 
isolates.   
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Figure 7.  Seven pairs of isolates further distinguished by EagI PFGE.  EagI 
digestion was used to demonstrate that the isolates digested by SmaI, shown in Figure 6, 
could be further distinguished by EagI digestion.  The original source of the isolates is 
shown.  The NRS100 control strain, obtained from NARSA, is included in this set of 
isolates. 
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Figure 8.  Seven pairs of isolates further distinguished by SacII PFGE.  SacII 
digestion was used to demonstrate that the isolates digested by SmaI, shown in Figure 6, 
could be further distinguished by SacII digestion.  The original source of the isolates is 
shown.  The NRS100 control strain, obtained from NARSA, is included in this set of 
isolates. 
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Selection of CA-MRSA Isolates for Multilocus Sequence Typing.  
 In order to explore the use of genomic typing methods for CA-MRSA 
subspeciation, 30 isolates that were previously typed by PFGE were chosen for MLST.  
The isolates were selected to represent both Florida and Washington State (Figure 9).  
CA-MRSA isolated from a variety of clinical sources including wounds, urine, blood, 
sputum, and nose were included to represent the variety of disease caused by S. aureus 
(Figure 9).  Furthermore, isolates possessing several pulsotypes as determined using the 
PFGE database were included (Figure 9).  Isolates with identical pulsotypes were also 
included among the 30 CA-MRSA as controls as shown in Figure 9.   
 
PCR Amplification of Housekeeping Genes for MLST 
Following isolation of genomic DNA, internal fragments of the following seven 
housekeeping genes; arc, aro, glp, gmk, pta, tpi, and yqi were amplified by PCR using 
the primers listed in Table 4.  PCR was performed according to the standardized protocol 
for S. aureus (saureus.mlst.net) for most isolates.  However, adjustment of the annealing 
temperature, increasing from 60°C to 65°C, was necessary for PCR amplification of the 
gmk, pta, and/or yqi genes for some isolates to obtain a single band for sequencing.  The 
PCR primers, primer dimers, and enzymes were removed from the amplification 
reactions prior to sequencing using the Wizard PCR Preps® kit and 1 μl of the resulting 
product was run on a gel to confirm a single band was present (Figure 10).    
 
 
 
 Figure 9.  BioNumerics® Analysis.  A UPGMA derived dendrogram illustrates the 
pulsotypes of the 30 CA-MRSA isolates used for MLST.   
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Figure 10.  PCR amplification of the internal fragment of the gmk gene for MLST.  
PCR reactions were purified using the Wizard PCR Preps® kit to remove primer dimers 
and amplification primers.  The result was a single band of 429 base pairs corresponding 
to the internal fragment of the gmk gene.  The marker used for all agarose gels was 
Promega Benchtop 1 Kb Ladder. 
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DNA Sequencing, Alignment, and Assigning of Alleles and Sequence Types for CA-
MRSA MLST. 
A minimum of four forward and reverse sequencing reactions were performed for 
each PCR product analyzed, comprising 28 sequencing reactions for each of the 30 
isolates examined.  The resulting DNA sequences were uploaded to the SeqMan® 
program for alignment. Each gene was analyzed separately for each isolate using both 
forward and reverse sequencing reactions to remove ambiguity in base calling.  The 
consensus sequence data from the alignments was then entered into the MLST database 
for comparison to known housekeeping gene sequences (alleles).  The online allele tool 
allowed consensus sequences to be cut and paste into the database and compared to 
known sequences.  Alleles were then assigned for the seven gene sequences from all 
isolates used in this study as each sequence matched a known allele present in the 
database (Table 8).  The resulting allelic pattern could then be entered into the database to 
assign a sequence type. For example, the following pattern, arcC – allele 3, aroE – allele 
3, glpF – allele 1, gmK – allele 1, pta – allele 4, tpi – allele 4, and yqi – allele 3 
corresponds to ST 8.  All isolates used in this study possess known STs as indicated in 
Table 8. As illustrated by Table 8 and Figure 11, there is little variation of the alleles 
present among the CA-MRSA isolates used for this study.  Although a large number of 
alleles have been described for each of the seven housekeeping genes (Table 9), our 
isolates failed to show much variation.  Consequently, despite the presence of 734 known 
STs in the S. aureus database, our isolates were comprised of only four sequence types 
(Table 8). 
 
57 
 
 
 
468arcF         TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATGCCATTGGATACT 60 
704arcF         TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATGCCATTGGATACT 60 
692arcF         TTATTAATCCAACAAGCTAAATCGAACAGTGACACAACGCCGGCAATGCCATTGGATACT 60 
                  ************************************************************ 
 
468arcF         TGTGGTGCAATGTCACAGGGTATGATAGGCTATTGGTTGGAAACTGAAATCAATCGCATT 120 
704arcF         TGTGGTGCAATGTCACAGGGTATGATAGGCTATTGGTTGGAAACTGAAATCAATCGCATT 120 
692arcF         TGTGGTGCAATGTCACAGGGTATGATAGGCTATTGGTTGGAAACTGAAATCAATCGCATT 120 
                      ************************************************************ 
 
468arcF         TTAACTGAAATGAATAGTGATAGAACTGTAGGCACAATCGTTACACGTGTGGAAGTAGAT 180 
704arcF         TTAACTGAAATGAATAGTGATAGAACTGTAGGCACAATCGTTACACGTGTGGAAGTAGAT 180 
692arcF         TTAACTGAAATGAATAGTGATAGAACTGTAGGCACAATCGTTACACGTGTGGAAGTAGAT 180 
                      ************************************************************ 
 
468arcF         AAAGATGATCCACGATTTGATAACCCAACTAAACCAATTGGTCCTTTTTATACGAAAGAA 240 
704arcF         AAAGATGATCCACGATTTGATAACCCAACTAAACCAATTGGTCCTTTTTATACGAAAGAA 240 
692arcF         AAAGATGATCCACGATTTGATAACCCAACTAAACCAATTGGTCCTTTTTATACGAAAGAA 240 
                  ************************************************************ 
 
468arcF         GAAGTTGAAGAATTACAAAAAGAACAGCCAGACTCAGTCTTTAAAGAAGATGCAGGACGT 300 
704arcF         GAAGTTGAAGAATTACAAAAAGAACAGCCAGACTCAGTCTTTAAAGAAGATGCAGGACGT 300 
692arcF         GAAGTTGAAGAATTACAAAAAGAACAGCCAGACTCAGTCTTTAAAGAAGATGCAGGACGT 300 
                  ************************************************************ 
 
468arcF         GGTTATAGAAAAGTAGTTGCGTCACCACTACCTCAATCTATACTAGAACACCAGTTAATT 360 
704arcF         GGTTATAGAAAAGTAGTTGCGTCACCACTACCTCAATCTATACTAGAACACCAGTTAATT 360 
692arcF         GGTTATAGAAAAGTAGTTGCGTCACCACTACCTCAATCTATACTAGAACACCAGTTAATT 360 
                  ************************************************************ 
 
468arcF         CGAACTTTAGCAGACGGTAAAAATATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTT 420 
704arcF         CGAACTTTAGCAGACGGTAAAAATATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTT 420 
692arcF         CGAACTTTAGCAGACGGTAAAAATATTGTCATTGCATGCGGTGGTGGCGGTATTCCAGTT 420 
                  ************************************************************ 
 
468arcF         ATAAAAAAAGAAAATACCTATGAAGGTGTTGAAGCG 456 
704arcF         ATAAAAAAAGAAAATACCTATGAAGGTGTTGAAGCG 456 
692arcF         ATAAAAAAAGAAAATACCTATGAAGGTGTTGAAGCG 456 
                  ************************************ 
 
Figure 11. Clustal W (1.82) multiple sequence alignment of arc housekeeping gene 
fragment.   Alignment of the sequences of the arc genes from three S. aureus isolates 
demonstrates 100% identity resulting in the assignment of the same allele at this loci for 
these isolates.   
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Strain Source State arcC aroE glpF gmk pta tpi yqi ST  
CBD0467 blood WA 1 4 1 4 12 1 10 5 
CBD0468 wound WA 3 3 1 1 4 4 3 8 
CBD0471 urine WA 1 4 1 4 12 1 10 5 
CBD0472 blood WA 1 4 1 4 12 1 10 5 
CBD0479 wound WA 3 3 1 1 4 4 3 8 
CBD0482 wound WA 1 4 1 4 12 1 10 5 
CBD0541 wound WA 3 3 1 1 4 4 3 8 
CBD0542 blood WA 1 4 1 4 12 1 28 105 
CBD0611 wound FL 3 3 1 1 4 4 3 8 
CBD0613 nose FL 1 4 1 4 12 1 10 5 
CBD0614 wound FL 1 4 1 4 12 1 10 5 
CBD0618 nose FL 1 4 1 4 12 1 10 5 
CBD0633 nose FL 1 4 1 4 12 1 28 105 
CBD0637 nose FL 1 4 1 4 12 1 10 5 
CBD0644 nose FL 1 4 1 4 12 1 10 5 
CBD0652 nose FL 1 4 1 4 12 1 10 5 
CBD0665 nose FL 3 3 1 1 4 4 3 8 
CBD0674 nose FL 3 3 1 1 4 4 3 8 
CBD0677 nose FL 3 3 1 1 4 4 3 8 
CBD0685 wound FL 3 3 1 1 4 4 3 8 
CBD0691 nose FL 10 14 8 6 10 3 2 45 
CBD0692 nose FL 3 3 1 1 4 4 3 8 
CBD0704 sputum FL 3 3 1 1 4 4 3 8 
CBD0717 nose FL 1 4 1 4 12 1 10 5 
CBD0727 blood FL 1 4 1 4 12 1 10 5 
CBD0728 blood FL 1 4 1 4 12 1 10 5 
CBD0734 nose FL 1 4 1 4 12 1 10 5 
CBD0736 nose FL 1 4 1 4 12 1 10 5 
CBD0737 wound FL 3 3 1 1 4 4 3 8 
CBD0885 urine FL 3 3 1 1 4 4 3 8 
 
Table 8.  Multilocus sequence typing alleles and sequence types for 30 S. aureus 
isolates.   Thirty S. aureus isolates were chosen for MLST which represent strains from 
both Florida and Washington State and clinical sources including nose, sputum, urine, 
blood, and wound isolates.  The alleles and ST types were assigned using the online S. 
aureus database and sequences obtained from the housekeeping genes of the 30 isolates. 
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TABLE 9.  Comparison of S. aureus MLST alleles 
Gene Total Alleles in Database Total Alleles in Present Study 
arcC 87 3 
aroE 129 3 
glpF  100 2 
gmk 71 3 
pta 98 3 
tpi 101 3 
yqiL 95 4 
 
 
 
Comparison of PFGE Data and MLST Data for 30 CA-MRSA Isolates. 
 
 A dendrogram was prepared for the 30 S. aureus isolates typed by MLST using 
the S. aureus PFGE database.  The isolates were grouped into 21 pulsotypes by PFGE, as 
compared to four STs, as shown in Figure 12.  Isolates did not cluster based on either the 
state in which they were isolated or on their disease manifestations.  Isolates with the 
same pulsotype always had the same MLST sequence type, however isolates with the 
same sequence type were frequently further differentiated by PFGE (Figure 12).   For 
example, CBD 0665 and CBD 0677 were both assigned to ST 8 by MLST, but the PFGE 
patterns differ by >7 bands. The largest cluster of isolates was a match to the USA 300 
epidemic clone (control not shown), which is also ST 8 by MLST (Figure 12).  Database 
searches for the four resulting STs determined that they are found worldwide (Table 10). 
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TABLE 10.  MLST Sequence Type Information  
ST Geographical Location (s) of ST Additional Information 
5 
UK, Thailand, US 
(MI,NY,PA,NJ,MD), Scotland, 
France, Belgium, Canada, Finland, 
Portugal, Japan, Netherlands, 
Poland, Columbia, Switzerland, 
Slovenia 
EMRSA 3 European endemic 
strain, isolated from blood, 
pus, etc in hospital.  Also 
frequently isolated from 
carriers in numerous countries.
8 
UK, Canada, Netherlands, Scotland, 
Ireland, Australia, US (NY,MD) 
France, Germany, Denmark, 
Sweden, Greece, Switzerland, 
Belgium 
EMRSA 2,6,7,12,13,14 
European endemic strains, 
isolated from blood, pus, etc in 
hospital.  Also frequently 
isolated from carriers in 
numerous countries 
45 
Canada, Belgium, Germany, 
Sweden, Finland, Netherlands, UK, 
US (NY), Australia, Switzerland 
European endemic strains, 
isolated from blood, pus, etc in 
hospital.  Also frequently 
isolated from carriers in 
numerous countries 
105 
US (FL), Switzerland Only 3 strains added to date, 1 
isolated from urine, two from 
unknown clinical source.  All 
isolates from hospital 
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Figure 12.  BioNumerics® analysis and MLST data. Dendrograms were derived from 
the unweighted pair group method using arithmetic averages and based on Dice 
coefficients.  Band position tolerance and optimization were set at 1.0%.  The sequence 
types for MLST as assigned using the online database (saureus.mlst.net) appear in the 
final column.   
 
 
 
 
61 
62 
 
 
 
 
 
PCR Amplification of spa Region of CA-MRSA 
 
 The 30 CA-MRSA isolates that were characterized by PFGE and MLST were 
further characterized by spa typing.   PCR was performed for the CA-MRSA using the 
genomic template isolated for MLST and the primers listed in Table 4.  Amplification for 
spa typing required the use of two different forward primers, spaF1 or spaF2 (Table 4).  
PCR amplification of all isolates was initially performed using the spaF1 primer.  These 
initial results indicated that CBD0614 produced a product that was much smaller in size 
than the rest of the isolates tested.  This isolate was amplified again using the spaF2 
primer which resulted in the same small sized fragment suggesting that this isolate 
possesses a low number of spa repeats (Figure 13).  The initial amplification of 
CBD0633 using the spaF1 primer failed but was successful using the spaF2 primer as 
shown in Figure 13.  Amplification of the spa region resulted in the same size fragments 
for all isolates except CBD0614 (Figure 13), CBD0633 (Figure 13), CBD0691 (Figure 
14), and CBD0885 (Figure 14).  The PCR primers, primer dimers, and enzymes were 
removed from the amplification reactions prior to sequencing using the Wizard PCR 
Preps® kit and 1 μl of the resulting product was run on a gel to confirm a single band was 
present (not shown). 
 
 
 
 
 
 
M
ar
ke
r
M
ar
ke
r
C
B
D
06
44
C
B
D
04
68
C
B
D
04
67
C
B
D
06
37
C
B
D
06
33
C
B
D
06
18
C
B
D
06
14
C
B
D
06
13
C
B
D
06
11
C
B
D
05
42
C
B
D
05
41
C
B
D
04
82
C
B
D
04
79
C
B
D
04
72
C
on
tr
ol
 
C
B
D
04
71
 
Figure 13. Amplification of spa region.  Polymerase chain reaction was performed on 
30 S. aureus isolates to amplify the spa region for molecular typing.  In the 15 isolates 
pictured, the amplified region ranged in size due to the number of 24 base pair spa 
repeats in each isolate.  CBD0614 possesses only two spa repeats, and CBD0633 
possesses only nine spa repeats, accounting for the small size of the products pictured, 
while the remaining isolates all contain 10 spa repeats.  The marker used on this gel was 
Promega Benchtop Ladder.  The last lane pictured was the no DNA control.    
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Figure 14. Amplification of spa region.  Polymerase chain reaction was performed on 
30 S. aureus isolates to amplify the spa region for molecular typing.  In the 15 isolates 
pictured, the amplified region ranged in size due to the number of 24 base pair spa 
repeats in each isolate.  CBD0691 possesses only seven, and CBD0885 only six spa 
repeats, accounting for the small size of the products pictured.  The remaining isolates all 
contain 10 spa repeats.  The marker used on this gel was Promega Benchtop Ladder.   
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DNA Sequencing, Alignment, and Assigning of Repeats and spa Types for CA-
MRSA spa Typing. 
 A minimum of four forward and four reverse sequencing reactions were 
performed for each PCR product analyzed, comprising 8 sequencing reactions for each of 
the 30 isolates examined.  The resulting DNA sequences were uploaded to the SeqMan® 
program for alignment.  The use of eight sequences for each isolate removed ambiguity 
in base calling.  The repeat regions were easily identified in the aligned sequences by 
visual examination of the consensus sequence (Figure 15).  The majority of the isolates in 
the study were found to contain 10 repeats (Table 11).  Exceptions included CBD0614 (2 
repeats), CBD0633 (9 repeats), CBD0691 (7 repeats) and CBD0855 (6 repeats) as shown 
in Table 11.  Each repeat region was then entered into the spa database for comparison to 
known spa repeats worldwide.  The online repeat finder allowed individual repeats to be 
cut and paste into the database and repeats assigned.  All isolates used in this study 
contained repeats of 24 base pairs that had previously been identified and were therefore 
able to be assigned numbers using the online tool (Table 11).  The pattern of the repeats 
was then entered into the database for comparison against known spa types and spa types 
were assigned when possible.  For example, CBD0479 contained 10 repeats with the 
following pattern: R11-19-12-21-17-34-24-34-22-25, a pattern previously identified, and 
assigned to spa type 8 (Table 11).   A total of six spa types were identified in the study, 
including spa type 2, spa type 8, spa type 586, and three isolates with unknown spa types 
that were not identical to one another.  Information from the worldwide database on the 
known spa types is presented in Table 12. 
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479             AAAAGAGGAAGACAATAACAAGCCTGGCAAAGAAGACAATAACAAGCCTGGCAAAGAAGA 60 
685             AAAAGAGGAAGACAATAACAAGCCTGGCAAAGAAGACAATAACAAGCCTGGCAAAGAAGA 60 
674             AAAAGAGGAAGACAATAACAAGCCTGGCAAAGAAGACAATAACAAGCCTGGCAAAGAAGA 60 
                ************************************************************ 
 
479             CAACAACAAGCCTGGTAAAGAAGACAACAACAAGCCTGGCAAAGAAGACGGCAACAAGCC 120 
685             CAACAACAAGCCTGGTAAAGAAGACAACAACAAGCCTGGCAAAGAAGACGGCAACAAGCC 120 
674             CAACAACAAGCCTGGTAAAGAAGACAACAACAAGCCTGGCAAAGAAGACGGCAACAAGCC 120 
                   ************************************************************ 
 
479             TGGTAAAGAAGACAACAAAAAACCTGGTAAAGAAGATGGCAACAAGCCTGGTAAAGAAGA 180 
685             TGGTAAAGAAGACAACAAAAAACCTGGTAAAGAAGATGGCAACAAGCCTGGTAAAGAAGA 180 
674             TGGTAAAGAAGACAACAAAAAACCTGGTAAAGAAGATGGCAACAAGCCTGGTAAAGAAGA 180 
                   ************************************************************ 
 
479             CAACAAAAAACCTGGTAAAGAAGACGGCAACAAGCCTGGCAAAGAAGATGGCAACAAACC 240 
685             CAACAAAAAACCTGGTAAAGAAGACGGCAACAAGCCTGGCAAAGAAGATGGCAACAAACC 240 
674             CAACAAAAAACCTGGTAAAGAAGACGGCAACAAGCCTGGCAAAGAAGATGGCAACAAACC 240 
                   ************************************************************ 
 
479             TGGT 244 
685             TGGT 244 
674             TGGT 244 
                  **** 
 
 
 
 
Figure 15. Clustal W (1.82) multiple sequence alignment for spa typing.   Alignment 
of the sequences of the spa genes from three S. aureus isolates demonstrates 100% 
identity resulting in the assignment of the same repeats and the same spa type for these 
three isolates.   
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TABLE 11.  Summary of spa repeats and spa type  
Strain Source State Repeat Pattern spa Type 
CBD0467 Blood WA R26-23-17-34-17-20-17-12-17-16 2 
CBD0468 Wound WA R11-19-12-21-17-34-24-34-22-25 8 
CBD0471 Urine WA R26-23-17-34-17-20-17-12-17-16 2 
CBD0472 Blood WA R26-23-17-34-17-20-17-12-17-16 2 
CBD0479 Wound WA R11-19-12-21-17-34-24-34-22-25 8 
CBD0482 Wound WA R26-23-17-34-17-20-17-12-17-16 2 
CBD0541 Wound WA R11-19-12-21-17-34-24-34-22-25 8 
CBD0542 Blood WA R26-23-17-34-17-20-17-12-17-16 2 
CBD0611 Wound FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0613 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0614 Wound FL R26-16 586 
CBD0618 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0633 Nose FL R26-23-17-34-17-12-17-17-16 Unknown 
CBD0637 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0644 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0652 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0665 Nose FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0674 Nose FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0677 Nose FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0685 Wound FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0691 Nose FL R8-16-2-43-34-17-34 Unknown 
CBD0692 Nose FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0704 Sputum FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0717 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0727 Blood FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0728 Blood FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0734 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0736 Nose FL R26-23-17-34-17-20-17-12-17-16 2 
CBD0737 Wound FL R11-19-12-21-17-34-24-34-22-25 8 
CBD0885 Urine FL R11-34-24-34-22-25 Unknown 
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TABLE 12.  Summary of spa Type Information 
ST Geographical Location (s) of ST Additional Information 
2 
France, Germany, Norway, Sweden, 
Denmark, Hungary, Austria, Italy, 
Belgium 
EMRSA-3, New York clone, 
Japan clone, Pediatric, Match 
to isolates with USA100 and 
USA800 pulsotypes. Matches 
isolates with MLST types 5, 
231, 113 
8 
Germany, France, Sweden, 
Norwary, Denmark, Netherlands, 
Austria, Italy, Belgium 
Northern German MRSA 
(subclone), Matched isolates 
with USA 300 pulsotype, 
Archaic/Iberian.  Matches 
isolates with MLST type 8. 
586 Germany Only 2 isolates in Germany, no further information available. 
 
 
 
 
Comparison of PFGE, MLST, and spa Typing Data for 30 CA-MRSA Isolates. 
 
 Sequence types and spa types were added to the dendrogram prepared for the 30 
S. aureus isolates using the S. aureus PFGE database (Figure 16).  The isolates were 
grouped into four sequence types by MLST and six spa types (Figure 16).  As previously 
noted in the worldwide database (Table 12) isolates with patterns consistent with USA 
300 controls were spa type 8, and isolates consistent with USA 100 controls were spa 
type 2 (control data not shown).  The 30 CA-MRSA isolates were assigned to four 
sequence types by MLST and six spa types by staphylococcal protein A typing.  
However, these subtypes were further differentiated into 21 pulsotypes by PFGE as 
demonstrated in Figure 17.   
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Figure 16.  BioNumerics® analysis including PFGE, MLST, and spa data. 
Dendrograms were derived from the unweighted pair group method using arithmetic 
averages and based on Dice coefficients.  Band position tolerance and optimization were 
set at 1.0%.  The sequence types for MLST appear in the second to last column and the 
spa types appear in the final column.   
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Figure 17.  Summary of PFGE pulsotypes, spa types, and Sequence types for 30 CA-
MRSA isolates.  Typing the 30 CA-MRSA resulted in 21 PFGE pulsotypes, 6 spa types, 
and 4 MLST sequence types as illustrated. 
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Discussion 
 
 Staphylococcus aureus causes a wide variety of diseases both within the hospital 
environment and in the community.   S. aureus is one of the most commonly diagnosed 
bacterial infections which causes diseases ranging from self-limiting food poisoning to 
life-threatening septicemia and pneumonia.  Control and treatment options for this 
organism are complicated by its remarkable ability to adapt to its environment especially 
through the acquisition of antibiotic resistance determinants.  The most alarming trend in 
recent years was the acquisition of methicillin resistance that rendered the use of all β-
lactam antibiotics useless for S. aureus infections.  More recently, MRSA strains have 
been identified in persons in the community who lack the traditional risk factors for S. 
aureus infection.  The CA-MRSA infections are of particular public health concern 
because they result in serious diseases including necrotizing fasciitis and necrotizing 
pneumonia.  The high morbidity, mortality, and cost of care for strains such as these 
highlights the need for public health, hospital, and other laboratories to accurately 
identify these microorganisms.  These factors illustrate the need for a proactive approach 
to surveillance, identification of hypervirulent strains, and infection control measures to 
prevent spread of the organism and to provide the most effective treatment options to 
patients.    
 In this project S. aureus isolates that were collected from Florida and Washington 
states and from a variety of clinical diseases were used to establish a large database of 
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DNA fingerprint patterns. Only community-acquired, methicillin-resistant isolates were 
included in this study.  The definition of community-acquired S. aureus includes isolates 
collected within 72 hours of hospitalization, non-multi-drug resistant isolates, and isolates 
collected from persons with no prior history of hospitalization (64).  The present study 
used slightly more stringent characteristics in that CA-MRSA is defined as isolates 
collected in an outpatient setting, or isolates collected no more than 48 hours after 
hospitalization, and only one isolate per patient was used in the analyses.  The DNA 
fingerprint patterns resulting from PFGE were analyzed using the BioNumerics® 
software package to create dendrograms used for phylogenetic comparison of the isolates.  
A total of 403 isolates were analyzed and compared to a number of control strains 
(Appendix 1).  Although a large number of the isolates included in the study 
demonstrated sporadic pulsotypes (Figure 2), the dendrogram contained two pulsotypes 
consistent with the control strains USA 300 and USA 100.  Identifying these repeat 
pulsotypes among the isolates was the first step in surveillance for hypervirulent clones 
and it established the presence of the epidemic CA-MRSA isolate USA 300 in both 
Florida and Washington states, geographic regions in which neither strain had previously 
been identified (91).   
A total of 136 of the CA-MRSA isolates analyzed possessed patterns consistent 
with USA 300 a strain that is known to carry the PVL toxin genes and to cause serious 
wound infection.  Consistent with other reports, the majority of these organisms were 
isolated from wound cultures, and most of the wound cultures included in this study 
contained the USA 300 strain.  This finding has important implications for public health 
measures to control the spread of this isolate.  First, this strain accounts for the greatest 
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majority of all of the isolates included in this study, a fact that is probably related to its 
epidemic potential as described in numerous other studies (12, 24, 70, 72, 110).  Second, 
the strain is known to carry the PVL toxin genes which likely contribute it its ability to 
cause serious diseases including necrotizing fasciitis and pneumonia in an otherwise 
healthy person with none of the usual risk factors related to S. aureus infection (12, 37, 
71).  Finally, this strain, while resistant to methicillin and therefore all of the β-lactam 
antibiotics, is not generally resistant to antimicrobials such as trimethoprim-
sulfamethoxazole (Bactrim®), and therefore the usual recommended treatment for 
MRSA, vancomycin, can be avoided.  The use of vancomycin for the treatment of MRSA 
should be discouraged as it is believed to contribute to the evolution of VRSA 
(vancomycin-resistant S. aureus) (45).  However, vancomycin is commonly used to treat 
MRSA as most cases are believed to be multi-drug resistant and therefore untreatable by 
any other antimicrobial therapy.  The knowledge that this strain is circulating within a 
community can be used along with other clinical factors to guide the treatment plan for 
patients.   
 The presence of the USA 100 strain among the CA-MRSA, accounting for 88 of 
the isolates included in this study, was unexpected as this isolate was previously reported 
as a hospital-acquired strain (70).   This strain was identified primarily in isolates from 
the nose and blood (Table 6).  It is interesting to note that USA 100 strain does not carry 
the PVL genes and has not been associated with any particular disease etiology in 
contrast to USA 300.  Therefore, it is possible that USA 100 is present in a large number 
of isolates collected from the nose because it is primarily involved in colonization rather 
than infection.  The presence of USA 100 in blood isolates is not easily interpreted due to 
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the low number of blood isolates included in this study.   There are two major public 
health implications of the presence of this strain in the community.  First, it appears that a 
classically hospital-acquired isolate has moved into the community (70).  Traditionally 
CA-MRSA included only those isolates harboring the SCCmec IV element.  In contrast, 
USA 100 carries the SCCmec type II resistance element.  Second, studies have shown 
that MRSA carriers are most likely to develop staphylococcal disease caused by the same 
isolate that they harbor (18, 19, 46).  The spread of isolates within the community, and 
from the hospital to the community, are both scenarios of public health concern.  One 
possible mechanism for the spread of epidemic clones from the hospital environment to 
the community may be transmission by asymptomatic carriers.  A study of CA-MRSA 
epidemiology suggested that surveillance for S. aureus isolates should include periodic 
nasal colonization studies, a method which could also be used to track the USA 100 
isolates (119).  Monitoring the rates of MRSA nasal carriage among otherwise healthy 
individuals followed by appropriate treatment to eliminate strains, even in persons who 
do not display symptoms of disease, may be warranted to stop the spread of epidemic 
strains.   
The identification of the two epidemic strains has illustrated the usefulness of 
PFGE in surveillance studies and it is to data considered the “Gold Standard” for typing 
of S. aureus isolates.  However, an unanswered concern regarding S. aureus PFGE is that 
the use of just one restriction enzyme does not explore the potential discriminatory power 
of the technique.  Studies using organisms such as Salmonella have demonstrated that the 
use of multiple enzymes often unmasked relationships that were not seen using single 
digest macrorestriction (88).  The present study demonstrated through the use of virtual 
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digestion that secondary enzymes could be identified for S. aureus PFGE (Table 7) but 
that the discriminatory power was unchanged by the use of more than one enzyme 
(Figures 3-8).  Therefore SmaI digestion is sufficient for S. aureus PFGE but 
unfortunately results in data that at present cannot easily be shared between laboratories.   
Compilation of data on the spread of CA-MRSA in the United States currently 
requires a review of the pertinent literature as no nationwide database for S. aureus exists.  
The CDC currently compiles DNA fingerprint data on a number of organisms to track 
food-borne outbreaks in a program referred to as PulseNet.  In a 2003 publication the 
CDC reported in house efforts at establishing a national database for MRSA (70).  
However, since that publication there has been no standardization of the S. aureus PFGE 
protocol, no guidelines for certifying laboratories to submit isolates, and conflicting 
information concerning the pulsotypes which are considered epidemic clones (70, 109).  
A standardized protocol will be required for S. aureus researchers to compare data and 
control strains will be necessary for each group to determine if epidemic isolates are 
circulating in their communities.  Furthermore, the criteria for certifying laboratories to 
submit data to PulseNet is extensive and the data flow is unidirectional.  One of the major 
concerns of PulseNet participants, as presented at the 2005 PulseNet Update Meeting in 
Atlanta, was that data is sent to CDC and no analysis is returned to the submitting group.  
Without a detailed report on the isolates present in the community the chain from 
identification to treatment is broken and the user gets very little out of participating in 
PulseNet.    
  As a result of requesting CA-MRSA isolates from various clinical entities this 
study essentially monitored those communities for the presence of S. aureus isolates of 
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interest during the period the isolates were collected.  Using the database created from 
PFGE data two epidemic S. aureus isolates were identified that could potentially have 
considerable public health impact.  Ideally this data could now be shared with clinicians 
working in the effected area.  However, the study was limited to distinct geographical 
areas, primarily Central Florida, and Washington State, and little is known how these 
isolates compare to those present in the rest of the United States or worldwide.  Such 
information would be of great value as data comparison would result in better 
understanding of how the isolates are spread which in turn can direct public health efforts 
to prevent their spread.  While the United States has not yet established a network for 
tracking S. aureus isolates, other countries such as Canada, Australia, and several 
European countries routinely track S. aureus isolates using PCR-based techniques (2, 25, 
77, 87). 
 The use of gel-based techniques for molecular typing has a considerable number 
of advantages and disadvantages as listed in Table 2.  PFGE is considered the “Gold 
Standard” for S. aureus typing due in large part to the following advantages listed in the 
table; high discriminatory power, all isolates are typeable, and results are highly 
reproducible.  Regardless of these advantages, the disadvantage of low portability of data 
and the time-consuming nature of performing PFGE makes the technique less than 
desirable for some public health applications.  As a consequence, efforts are underway to 
identify a technique that is fast, has high discriminatory power, and results in highly 
portable data.  Any technique that results in numerical or sequence data is going to be 
highly portable while those involving analysis of gels are no more applicable than PFGE.  
Therefore the many available techniques that involve restriction digest to generate 
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fingerprints such as REA, riboprinting, and MLEE were not considered for this study.  
The PCR and sequence-based techniques such as multilocus sequence typing that directly 
compares sequence data for the presence of single nucleotide changes, and spa typing in 
which tandem repeats in a particular genomic region are analyzed and compared, were 
considered the best options for this study.  These two typing techniques have been 
extensively used in characterizing S. aureus isolates overseas but neither has been applied 
to the study of CA-MRSA isolates in the United States.  Thirty isolates from the PFGE 
database which represent both Florida and Washington, a number of disease etiologies, 
and a variety of pulsotypes as determined by PFGE, were analyzed by both MLST and 
spa typing (Figure 9).  The goal of this analysis was to determine if these PCR-based 
techniques would be useful in identifying the hypervirulent clones among the CA-MRSA 
isolates thereby providing an alternative to PFGE typing.   
 Multilocus sequence typing was performed on the 30 isolates according to the 
well-established protocol and resulted in allele assignment and sequence types for all 
isolates tested (Table 8).  The genes used for the MLST were housekeeping genes that are 
present in all isolates with has two advantages for the technique.  First, these genes must 
be present in all S. aureus isolates so therefore all isolates should be typeable by MLST.  
Second, variation in the housekeeping genes is slow and genetic relationships between 
clones can therefore be detected.   Unfortunately, there is little variation in the 
housekeeping genes among CA-MRSA isolates as demonstrated in Table 8.  Sequence 
results from one of the regions, internal fragment of the glp gene, demonstrated the same 
result for all isolates, except one (CBD0691), indicated that nearly all of the isolates have 
the same allele at this locus.  Alleles with no variation such as this are of no value to the 
78 
technique and omission of this gene would have resulted in the same overall result.  The 
lack of variation among the isolates resulted in only 4 STs identified among the 30 CA-
MRSA isolates.  Furthermore, isolates with significantly different PFGE patterns, as well 
as different phenotypes (data not shown), such as CBD0885 and CBD0467, possessed the 
same allelic pattern and were therefore assigned to the same sequence type.   
 The MLST approach was designed to measure the evolutionary differences 
between S. aureus isolates.  Variations in housekeeping genes accumulate very slowly 
and MLST is therefore suitable to measure changes among specific clones.  MLST has 
been used successfully to create models for the evolution of MRSA from MSSA 
ancestors and these studies have concluded that MRSA has arisen from at least 5 different 
lineages (27-29, 31-33).  The significance of this is that isolates identified in any location 
can be compared using the eBURST algorithm to determine how MRSA was introduced 
into a specific geographic location.  Studies such as these using MLST have 
demonstrated that MRSA evolved from MSSA strains already present within a country in 
some cases such as Denmark, Germany, and France.  Understanding the long-term 
epidemiology of the spread of MRSA isolates worldwide will likely contribute to efforts 
to control the spread of other S. aureus strains of interest.  For example, other studies 
have demonstrated the spread of antibiotic resistance genes, other than mecA, and 
virulence determinants, such as toxin genes, within particular clonal complexes as 
defined by MLST (113).  Each of these studies involved the evolution of a set of 
genetically related isolates, often described as a clone.  However, highly related isolates 
such as the 30 CA-MRSA isolates used in this study may belong to the same clonal 
complex and the same clone, but these clones may contain isolates with considerably 
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different pathogenic potential.  Isolates belonging to the same clone as defined by MLST 
in this study were associated with different disease etiologies, possessed different 
virulence factors, and varied in their resistance patterns (data not shown), all of which 
contribute to the public health measures necessary for their control and the available 
treatment options.  Therefore it is often necessary to identify S. aureus at the strain level 
rather than the level of a particular clone, especially when treatment options are 
considered. 
 The relatively stable “core” genome of the S. aureus isolates renders the MLST 
housekeeping gene protocol of little use for typing highly related strains such as MRSA 
and particularly CA-MRSA which has only been identified in the United States in the last 
6 years.  Modification of the existing MLST protocol to eliminate genes of little use such 
as glp and replacing them with hypervariable genes such as surface antigen genes may 
increase the discriminatory power of the technique.  A mix of both conserved and 
hypervariable genes may be required for adequate discriminatory power that represents 
the true relationship at the level of the strain and still corresponds to clinical significance.  
Conversely, it is entirely possible that the use of too many genes may result in closely 
related stains appearing different due to the increased discriminatory power.  
Experimentation with different combinations of conserved and hypervariable genes will 
be required to create a more discriminatory MLST protocol for S. aureus.  However, 
regardless of the genes used another major disadvantage of the MLST approach is that it 
is comparable to PFGE in the amount of time required for the analysis.  The required 
PCR amplification and sequencing of seven genomic regions was not only time-
consuming but significant ambiguity existed in the assignment of alleles for each region.  
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Although multiple sequence reactions were prepared in both the forward and reverse 
directions, the sequence-calling software often gave numerous results for the same 
nucleotide leading to repeat sequencing.  Furthermore, the large number of sequences 
required for the assignment of an ST type for a single isolate is costly when compared to 
PFGE.    
 The major advantage of the technique was that multilocus sequence typing 
resulted in data that was highly portable and was easily compared to MLST results 
obtained for strains worldwide using the online database.  The four STs identified among 
the 30 CA-MRSA isolates were present in the database indicating that they had been 
identified in other studies.  For each of the four STs, the database contained information 
concerning the geographic locations in which isolates with the same ST have been 
identified.  Significantly, the database also contains information on the background of the 
isolates deposited including such information as clinical site of infection, carrier status, 
matches to known epidemic clones, and PFGE patterns (Table 10).  However, the 
database is limited to mostly European countries as MLST typing in the rest of the world 
is rarely performed.  A more comprehensive database would be desirable for continued 
use of this technique, but a similar typing technique that is not as time-consuming or as 
costly, but results in higher discriminatory power would be more applicable.   
 Several recent studies have demonstrated the applicability of spa typing for typing 
S. aureus isolates of interest (1, 41, 59, 83, 103, 106).  This technique is attractive in that 
in requires PCR amplification of only the variable region of the spa gene followed by 
sequencing as opposed to the PCR amplification of seven regions required for MLST.  
Consequently, the amount of time required and costs involved in spa typing are 
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considerably less than MLST.  The 30 CA-MRSA isolates that were typed by MLST 
were characterized by spa typing in the hopes that this technique would be highly 
discriminatory, rapid, and inexpensive.   The spa typing technique proved to be more 
rapid than either MLST or PFGE in that results could be obtained in 48 hours as opposed 
to five days required for the other two techniques.  Sequencing of the relatively short spa 
repeat regions resulted in sequence data that was unambiguous and much more quickly 
analyzed in comparison to MLST data.  However, as with MLST, the discriminatory 
power of spa typing for the CA-MRSA isolates was considerably less than that of PFGE 
with only 6 distinct spa types present among the isolates as compared to 21 distinct 
pulsotypes (Table 11).  Furthermore, although all of the repeats identified in this study 
were present in the spa database, the pattern of three of the isolates was unknown and 
these could therefore not be assigned to spa types.  As demonstrated with the MLST data, 
spa typing data could be used to search the worldwide database for information regarding 
the spread of particular spa types, once again including geographical location, clinical 
data, MLST typing data, and pulsotypes (Table 12).  Technically, because spa typing was 
able to further differentiate subtypes within sequence types defined by MLST, it is the 
more discriminatory of the two techniques but insomuch as analysis of CA-MRSA 
isolates is concerned, it does not approach the discriminatory power of PFGE.   
 The variability of the spa gene between MSSA and MRSA isolates appears to be 
considerably higher than that among CA-MRSA isolates and spa typing has been used 
successfully to differentiate epidemic and sporadic isolates during nosocomial outbreaks 
(103).  At least two European hospitals have reportedly replaced PFGE with spa typing 
for analyzing S. aureus isolates present in their facilities (1, 2, 41).  Similar to MLST 
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studies, spa typing was used to determine that MRSA strains present in Portugal are not 
descended from long-established MSSA strains present within the country but were likely 
imported from abroad (1).  Another study of nosocomial outbreaks determined that in 
each case where spa types were different between isolates, other typing techniques 
confirmed that the isolates were in fact not related (106).  The same study also suggested, 
and has been demonstrated in the present study, that isolates with the same spa type are 
not necessarily epidemiologically related (106).  The use of spa typing for tracking S. 
aureus isolates for some applications such as nosocomial spread of isolates and its 
considerable advantages in terms of time and portability of data would be useful as an 
initial screen to rule out the necessity of more discriminatory technique such as PFGE.   
 The presence of S. aureus isolates with increased virulence, antibiotic resistance 
determinants, and high transmissibility is a major public health concern.  Active 
surveillance and application of the appropriate infection control measures will be 
required to control the spread of these strains.  In the present study molecular methods for 
typing S. aureus isolates, the first step in surveillance, were compared for their ability to 
type a set of closely related CA-MRSA isolates.  No one particular method excelled at 
typing these isolates in terms of discriminatory power, length of analysis, cost, and 
portability of data.  These data suggest that the technique used for typing should be 
selected based on the purpose of the typing study.  Cost and availability of the required 
equipment will of course also determine what typing methods can be used to type S. 
aureus.   All of the techniques discussed herein require highly specialized and costly 
equipment including PFGE gel boxes, thermocyclers, and nucleic acid sequencers.  Many 
laboratories may not have access to any of this equipment and may be required to send 
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samples to other laboratories for testing.  However, an ever-increasing number of hospital 
and public health laboratories do have access to this equipment and an application of each 
of the techniques to particular studies follows. 
 Infection control in a hospital environment is critical to prevent acquisition of 
nosocomial infection.  Outbreaks of nosocomial infection caused by S. aureus in the 
hospital environment are common and can be caused by either MSSA or MRSA.  
Infection control measures must be implemented to control the spread as quickly as 
possible but what measures are used depends on the extent of the spread.  For example, if 
the surgical and ICU wards are both reporting S. aureus outbreaks, it is imperative that 
the infection control practitioners know if the same strain is responsible for the outbreaks 
in both locations.  A quick way to determine if the strains are different is to use spa 
typing.  Strains with different spa types are epidemiologically unrelated and therefore 
infection control measures unique to each ward should be initiated.   Conversely, those 
strains with identical spa types may be related, and this could then be confirmed using 
PFGE.  In this case, the outbreak is likely from a common source and efforts should be 
directed at identifying infected personnel working in both wards or shared equipment.    
Following this same scenario, spa typing could then be used to rule out infection from 
healthcare workers who may be colonized with S. aureus.  In the event of a matching spa 
type, PFGE could then be used to confirm the outbreak strain originated with the 
healthcare worker.  Infection control measures can then be aimed at treating the 
healthcare worker as well as providing infection control prevention education.  Another 
use of spa typing is to rule out recurrent infection in carriers as opposed to successive 
infection with a different strain.  An initial screening by spa typing can aid in determining 
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if post-surgical infections are most likely to occur due to the patient’s own flora or 
nosocomially-acquired infection as hospital-acquired strains are significantly different in 
spa types from community-acquired S. aureus.  Finally, in an outbreak situation where 
PFGE confirmed that USA 300 is present in the community, strains from a patient with a 
wound infection who is otherwise healthy can be analyzed by spa typing to determine if 
the strain belongs to ST 8 consistent with all USA 300 isolates.  This patient could then 
be considered part of the outbreak and treated with the appropriate antibiotics.  Although 
most of the studies that are listed above as examples of spa typing applications could also 
be performed using MLST, spa typing for these applications has considerable advantages 
in terms of time and cost. 
 Large-scale epidemiological studies are often more concerned with the origins of 
the strains present in a geographic location during a particular time frame.  MLST studies 
have been used to track the origins of MRSA in many countries, and have in particular 
demonstrated that MRSA originated when MSSA strains previously identified in the 
country developed methicillin-resistance by acquisition of one of the SCCmec mobile 
elements.  These studies have provided a considerable amount of data concerning the 
worldwide spread of antibiotic-resistant strains.  Further applications of this technique 
will be to track the worldwide spread of the Panton-Valentine Leukocidin toxin genes, 
other newly described toxin genes, and other virulence factors.  MLST analysis of strains 
that are present in a particular community over a long time period will demonstrate which 
clonal complexes are most successful in that community.  Analysis of the strains present 
within that clonal complex can then be used to determine what factors likely determine 
the evolutionary advantage that allows those strains to be successful.  Although spa 
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typing can be used for similar studies, the lack of an algorithm to define the precise 
evolutionary relationships between spa types, as is present for sequence types in the 
eBURST analysis program, limits the use of spa typing for long-term evolutionary 
studies. 
 As demonstrated with the CA-MRSA isolates, often it is only the most 
discriminatory of the techniques that is required for a particular study.  Only PFGE was 
able to identify the presence of the USA 300 isolates in Florida and Washington State.  
The presence of this highly virulent, highly transmissible pathogen in the community has 
significant public health consequences.  The treatment of these patients can be guided by 
the knowledge that this strain carries the methicillin-resistance SCCmec IV element and 
is known to be susceptible to other antibiotics, negating the need to perform antibiotic 
susceptibility testing, and hopefully preventing the use of vancomycin to treat the 
infection.  It is well known that this isolate is easily spread among athletes, prisoners, and 
others sharing common facilities which can guide infection control measures within these 
facilities.  Often hospitals are contaminated with particular isolates for long periods of 
time and the source of the isolates are never discovered.  Detailed information regarding 
the susceptibilities of these nosocomial inhabitants is often well known and nosocomial 
infections within that facility are treated accordingly.  PFGE testing of hospital strains 
can determine what isolates are present and therefore more likely to cause nosocomial 
infection and have in the past detected changes from one dominant strain to another, 
leading to changes in the appropriate therapy.  Periodic nasal colonization studies in the 
community can be used to determine what strains are present among carriers.  These 
strains are important as most S. aureus infections are caused by the person’s normal flora.  
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As demonstrated in the present study, PFGE identified the USA 100 epidemic clone 
among community-acquired S. aureus isolates.  The public health significance of this 
finding is that a traditionally hospital-acquired MRSA is present in large numbers in the 
community.  This data can be used to create a model for the spread of this isolate and to 
guide public health efforts to prevent further spread.   As mentioned above, the use of spa 
typing can rule out infections with identical strains in many cases, but PFGE must be 
used to confirm that the strains are in fact identical.  Although PFGE provides 
considerable advantages in terms of discriminatory power, global studies involving the 
technique will have to wait for the establishment of PFGE fingerprinting databases and 
standardized protocols.  
 Surveillance programs for the spread of S. aureus isolates should be implemented 
by laboratories at the local, state, federal, and worldwide levels to guide infection control 
practices, to determine effective treatment therapies, to describe the epidemiology of the 
spread of S. aureus, and to study the evolution of the strains.  No one typing method is 
available to address all of these areas.  Those typing methods such as PFGE that detect 
rapid variation are well-suited to outbreak investigations, while the typing methods that 
categorize isolates by relatively stable genetic loci such as MLST and spa typing are 
more suited to long-term epidemiological and evolutionary studies.   
Future studies should include improvements to each of the techniques.  A 
worldwide database of DNA fingerprint patterns obtained using a standardized PFGE 
protocol is necessary to address the issue of portability of data.  Furthermore, newer 
PFGE protocols for S. aureus are under development to shorten the time period required 
for analysis.  Modification of the MLST protocol to include both variable and highly-
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conserved genes is necessary to increase the discriminatory power of the technique.   The 
development of guidelines to determine the genetic relationships between spa types is 
necessary for this technique to be useful for evolutionary studies.  Finally, efforts should 
continue to test existing typing techniques and to develop newer techniques that provide 
reliable, portable, typing data rapidly and at low cost.    
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Appendix A.  List of all Staphylococcus aureus isolates in BioNumerics® database 
 
 
Number CBD Number Origin Source Antibiotype Pulsotype
1 CBD0007 Feces ATCC Unknown Sporadic
2 CBD0019 Food DuPont Unknown Sporadic
3 CBD0034 Wound Fisher Scientific MSSA Sporadic
4 CBD0035 Food Dept. of Health Unknown Sporadic
5 CBD0036 Feces ATCC Unknown Sporadic
6 CBD0044 Unknown ATCC MSSA Sporadic
7 CBD0064 Unknown ATCC Unknown Sporadic
8 CBD0467 Sputum WA MRSA Sporadic
9 CBD0468 Wound WA MRSA USA 300
10 CBD0469 Blood WA MRSA USA 300
11 CBD0470 Sputum WA MRSA Sporadic
12 CBD0471 Urine WA MRSA Sporadic
13 CBD0472 Blood WA MRSA Sporadic
14 CBD0473 Sputum WA MSSA Sporadic
15 CBD0474 Wound WA MSSA Sporadic
16 CBD0475 Wound WA MSSA Sporadic
17 CBD0476 Urine WA MSSA USA 400
18 CBD0477 Wound WA MSSA Sporadic
19 CBD0478 Wound WA MRSA Sporadic
20 CBD0479 Wound WA MRSA Sporadic
21 CBD0480 Sputum WA MRSA Sporadic
22 CBD0481 Blood WA MRSA Sporadic
23 CBD0482 Wound WA MRSA Sporadic
24 CBD0483 Sputum WA MRSA Sporadic
25 CBD0484 Blood WA MRSA USA 100
26 CBD0485 Sputum WA MRSA USA 100
27 CBD0486 Wound WA MRSA Sporadic
28 CBD0504 Unknown FL MSSA Sporadic
29 CBD0505 Unknown LifeLink MSSA Sporadic
30 CBD0526 Wound WA MSSA Sporadic
31 CBD0527 Wound WA MSSA Sporadic
32 CBD0528 Wound WA MSSA Sporadic
33 CBD0529 Wound WA MSSA Sporadic
34 CBD0530 Body Fluid WA MSSA Sporadic
35 CBD0531 Wound WA MSSA Sporadic
36 CBD0532 Wound WA MSSA Sporadic
37 CBD0533 Sputum WA MSSA Sporadic
38 CBD0534 Sputum WA MSSA Sporadic
39 CBD0535 Sputum WA MSSA Sporadic
40 CBD0536 Sputum WA MSSA Sporadic
41 CBD0537 Sputum WA MSSA Sporadic
42 CBD0538 Sputum WA MSSA Sporadic
43 CBD0539 Wound WA MRSA USA 300
44 CBD0540 Wound WA MRSA USA 300
45 CBD0541 Wound WA MRSA USA 300
46 CBD0542 Blood WA MRSA USA 100
47 CBD0543 Unknown Unknown MRSA Sporadic
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48 CBD0544 Wound ATCC MSSA Sporadic
49 CBD0545 Sputum ATCC MSSA Sporadic
50 CBD0546 Marine Sponge FL MSSA Sporadic
51 CBD0611 Wound FL MRSA USA 300
52 CBD0612 Wound FL MRSA USA 300
53 CBD0613 Nose FL MRSA USA 100
54 CBD0614 Wound FL MRSA USA 100
55 CBD0615 Blood FL MRSA USA 100
56 CBD0616 Blood FL MRSA Sporadic
57 CBD0617 Wound FL MRSA Sporadic
58 CBD0618 Nose FL MRSA USA 100
59 CBD0619 Nose FL MRSA USA 100
60 CBD0620 Urine FL MRSA USA 100
61 CBD0621 Nose FL MRSA USA 100
62 CBD0622 Urine FL MRSA USA 100
63 CBD0623 NRS 77 NARSA Unknown PFGE Standard
64 CBD0624 Nose FL MRSA USA 100
65 CBD0625 Nose FL MRSA USA 100
66 CBD0626 Nose FL MRSA USA 100
67 CBD0627 Cervix FL MRSA Sporadic
68 CBD0628 Feces FL MRSA Sporadic
69 CBD0629 Blood FL MRSA Sporadic
70 CBD0630 Nose FL MRSA USA 100
71 CBD0631 Blood FL MRSA USA 100
72 CBD0632 Sputum FL MRSA Sporadic
73 CBD0633 Nose FL MRSA Sporadic
74 CBD0634 Blood FL MRSA USA 100
75 CBD0635 Blood FL MRSA USA 100
76 CBD0636 Nose FL MRSA USA 100
77 CBD0637 Nose FL MRSA USA 100
78 CBD0638 Nose FL MRSA USA 100
79 CBD0639 Nose FL MRSA USA 100
80 CBD0640 Wound FL MRSA USA 300
81 CBD0641 Nose FL MRSA USA 100
82 CBD0642 Nose FL MRSA USA 100
83 CBD0643 Nose FL MRSA Sporadic
84 CBD0644 Nose FL MRSA Sporadic
85 CBD0645 Nose FL MRSA Sporadic
86 CBD0646 Wound FL MRSA USA 100
87 CBD0647 Wound FL MRSA USA 100
88 CBD0648 Blood FL MRSA USA 100
89 CBD0649 Blood FL MRSA Sporadic
90 CBD0650 Sputum FL MRSA Sporadic
91 CBD0651 Nose FL MRSA USA 100
92 CBD0652 Nose FL MRSA Sporadic
93 CBD0653 Blood ATCC MRSA Sporadic
94 CBD0654 NRS100 NARSA MRSA Sporadic
95 CBD0655 NRS271A NARSA MRSA Sporadic
96 CBD0656 NRS271B NARSA MRSA Sporadic
97 CBD0662 Sputum FL MRSA Sporadic
98 CBD0663 Nose FL MRSA USA 100
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99 CBD0664 Nose FL MRSA Sporadic
100 CBD0665 Nose FL MRSA Sporadic
101 CBD0666 Blood FL MRSA USA 100
102 CBD0667 Blood FL MRSA Sporadic
103 CBD0668 Blood FL MRSA Sporadic
104 CBD0669 Nose FL MRSA USA 300
105 CBD0670 Nose FL MRSA USA 100
106 CBD0671 Nose FL MRSA USA 100
107 CBD0672 Nose FL MRSA Sporadic
108 CBD0673 Nose FL MRSA USA 100
109 CBD0674 Nose FL MRSA USA 300
110 CBD0675 Nose FL MRSA Sporadic
111 CBD0676 Nose FL MRSA USA 100
112 CBD0677 Nose FL MRSA Sporadic
113 CBD0678 Nose FL MRSA USA 100
114 CBD0679 Sputum FL MRSA Sporadic
115 CBD0680 Sputum FL MRSA Sporadic
116 CBD0681 Nose FL MRSA USA 100
117 CBD0682 Nose FL MRSA Sporadic
118 CBD0683 Nose FL MRSA USA 100
119 CBD0684 Nose FL MRSA Sporadic
120 CBD0685 Wound FL MRSA USA 300
121 CBD0686 Nose FL MRSA USA 100
122 CBD0687 Nose FL MRSA USA 100
123 CBD0688 Nose FL MRSA Sporadic
124 CBD0689 Blood FL MRSA USA 300
125 CBD0690 Nose FL MSSA USA 100
126 CBD0691 Nose FL MRSA Sporadic
127 CBD0692 Nose FL MRSA Sporadic
128 CBD0693 Nose FL MRSA USA 100
129 CBD0694 Nose FL MRSA Sporadic
130 CBD0695 Nose FL MRSA Sporadic
131 CBD0696 Blood FL MRSA USA 100
132 CBD0697 Nose FL MRSA USA 300
133 CBD0698 Nose FL MRSA USA 100
134 CBD0699 Nose FL MRSA USA 100
135 CBD0700 Nose FL MRSA USA 300
136 CBD0701 Nose FL MRSA Sporadic
137 CBD0702 Nose FL MRSA USA 300
138 CBD0703 Nose FL MRSA USA 100
139 CBD0704 Sputum FL MRSA Sporadic
140 CBD0705 Nose FL MRSA Sporadic
141 CBD0706 Nose FL MRSA USA 100
142 CBD0707 Nose FL MRSA USA 100
143 CBD0708 Nose FL MRSA Sporadic
144 CBD0709 Nose FL MRSA Sporadic
145 CBD0710 Nose FL MRSA USA 100
146 CBD0711 Nose FL MRSA USA 100
147 CBD0712 Nose FL MRSA USA 300
148 CBD0713 Nose FL MRSA Sporadic
149 CBD0714 Nose FL MRSA Sporadic
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150 CBD0715 Feces FL MRSA USA 100
151 CBD0716 Nose FL MRSA USA 100
152 CBD0717 Nose FL MRSA USA 100
153 CBD0718 Sputum FL MRSA Sporadic
154 CBD0719 Sputum FL MRSA Sporadic
155 CBD0720 Nose FL MRSA Sporadic
156 CBD0721 Nose FL MRSA Sporadic
157 CBD0722 Nose FL MRSA Sporadic
158 CBD0723 Nose FL MRSA Sporadic
159 CBD0724 Nose FL MRSA USA 600
160 CBD0725 Nose FL MRSA Sporadic
161 CBD0726 Nose FL MRSA USA 300
162 CBD0727 Blood FL MRSA USA 100
163 CBD0728 Blood FL MRSA USA 100
164 CBD0729 Nose FL MRSA Sporadic
165 CBD0730 Nose FL MRSA Sporadic
166 CBD0731 Nose FL MRSA USA 100
167 CBD0732 Nose FL MRSA USA 100
168 CBD0733 Nose FL MRSA USA 100
169 CBD0734 Nose FL MRSA USA 100
170 CBD0736 Nose FL MRSA Sporadic
171 CBD0737 Wound FL MRSA USA 300
172 CBD0738 Wound FL MRSA USA 300
173 CBD0739 Sputum FL MRSA USA 300
174 CBD0740 Wound FL MRSA USA 300
175 CBD0741 Nose FL MRSA USA 300
176 CBD0742 Nose FL MRSA Sporadic
177 CBD0743 Blood FL MRSA USA 100
178 CBD0744 Nose FL MRSA USA 100
179 CBD0745 Nose FL MRSA USA 100
180 CBD0786 Unknown FL MRSA USA 300
181 CBD0787 Wound FL MRSA USA 300
182 CBD0788 Wound FL MRSA USA 300
183 CBD0789 Wound FL MRSA USA 300
184 CBD0790 Wound FL MRSA Sporadic
185 CBD0791 Unknown FL MRSA USA 300
186 CBD0792 Unknown FL MRSA USA 300
187 CBD0793 Unknown FL MRSA USA 300
188 CBD0794 Unknown FL MRSA USA 300
189 CBD0795 Unknown FL MRSA USA 300
190 CBD0796 Unknown FL MSSA USA 300
191 CBD0797 N315 NARSA MRSA Sporadic
192 CBD0798 N123 NARSA MRSA USA 400
193 CBD0799 Unknown Unknown MRSA Sporadic
194 CBD0800 Unknown Unknown MRSA Sporadic
195 CBD0801 Unknown Unknown MRSA Sporadic
196 CBD0802 Unknown Unknown MRSA Sporadic
197 CBD0803 Unknown Unknown MRSA Sporadic
198 CBD0804 Unknown Unknown MRSA Sporadic
199 CBD0834 Wound FL MRSA USA 300
200 CBD0835 Wound ATCC MSSA Sporadic
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201 CBD0836 Wound ATCC MSSA Sporadic
202 CBD0842 Wound FL MRSA USA 300
203 CBD0843 Wound FL MRSA USA 300
204 CBD0844 Wound FL MRSA Sporadic
205 CBD0845 Rectum FL MRSA USA 100
206 CBD0846 Wound FL MRSA USA 100
207 CBD0847 Wound FL MRSA USA 100
208 CBD0848 Wound FL MRSA Sporadic
209 CBD0849 Wound FL MRSA USA 300
210 CBD0850 Wound FL MRSA Sporadic
211 CBD0851 Wound FL MRSA USA 300
212 CBD0852 Wound FL MRSA Sporadic
213 CBD0853 Eye FL MRSA USA 300
214 CBD0854 Wound FL MRSA USA 300
215 CBD0855 Wound FL MRSA Sporadic
216 CBD0856 Wound FL MRSA USA 300
217 CBD0857 Wound FL MRSA USA 100
218 CBD0858 Wound FL MRSA USA 300
219 CBD0859 Wound FL MRSA Sporadic
220 CBD0860 Wound FL MSSA Sporadic
221 CBD0861 Nose FL MRSA USA 300
222 CBD0863 Wound FL MRSA USA 300
223 CBD0864 Wound FL MRSA Sporadic
224 CBD0865 Wound FL MRSA USA 300
225 CBD0866 Wound FL MRSA USA 300
226 CBD0867 Wound FL MRSA USA 300
227 CBD0868 Wound FL MRSA USA 300
228 CBD0869 Wound FL MRSA USA 300
229 CBD0870 Wound FL MRSA USA 300
230 CBD0871 Wound FL MRSA USA 300
231 CBD0872 Wound FL MRSA USA 300
232 CBD0873 Wound FL MRSA Sporadic
233 CBD0874 Wound FL MRSA Sporadic
234 CBD0875 Wound FL MRSA Sporadic
235 CBD0876 Wound FL MRSA USA 300
236 CBD0877 Wound FL MRSA USA 300
237 CBD0878 Eye FL MRSA Sporadic
238 CBD0879 Wound FL MRSA USA 300
239 CBD0880 Eye FL MRSA USA 100
240 CBD0881 Wound FL MRSA USA 300
241 CBD0882 Wound FL MRSA USA 300
242 CBD0883 Wound FL MRSA USA 300
243 CBD0884 Unknown FL MRSA USA 100
244 CBD0885 Urine FL MRSA Sporadic
245 CBD0886 Unknown FL MRSA Sporadic
246 CBD0887 Wound FL MRSA USA 300
247 CBD0888 Urine FL MRSA USA 100
248 CBD0889 Wound FL MRSA USA 300
249 CBD0890 Urine FL MRSA Sporadic
250 CBD0891 Wound FL MRSA USA 300
251 CBD0892 Wound FL MRSA Sporadic
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252 CBD0893 Wound FL MRSA USA 300
253 CBD0894 Wound FL MRSA USA 300
254 CBD0895 Wound FL MRSA USA 300
255 CBD0896 Wound FL MRSA Sporadic
256 CBD0897 Unknown FL MRSA USA 100
257 CBD0898 Wound FL MRSA Sporadic
258 CBD0899 Wound FL MRSA USA 300
259 CBD0900 Wound FL MRSA USA 100
260 CBD0901 Wound FL MRSA USA 300
261 CBD0902 Urine FL MRSA Sporadic
262 CBD0903 Wound FL MRSA Sporadic
263 CBD0904 Unknown FL MRSA Sporadic
264 CBD0905 Wound FL MRSA USA 100
265 CBD0906 Wound FL MRSA USA 300
266 CBD0907 Wound FL MRSA USA 300
267 CBD0908 Wound FL MRSA USA 300
268 CBD0909 Wound FL MRSA Sporadic
269 CBD0910 Wound FL MRSA USA 300
270 CBD0911 Wound FL MRSA USA 100
271 CBD0912 Unknown FL MRSA USA 300
272 CBD0913 Wound FL MRSA USA 300
273 CBD0914 Wound FL MRSA USA 300
274 CBD0915 Wound FL MRSA Sporadic
275 CBD0916 Wound FL MRSA USA 100
276 CBD0917 Wound FL MRSA USA 100
277 CBD0918 Wound FL MRSA Sporadic
278 CBD0919 Wound FL MRSA Sporadic
279 CBD0920 Wound FL MRSA USA 300
280 CBD0921 Wound FL MRSA USA 100
281 CBD0922 Wound FL MRSA USA 100
282 CBD0923 Wound FL MRSA USA 300
283 CBD0924 Wound FL MRSA USA 100
284 CBD0925 Wound FL MRSA USA 100
285 CBD0926 Wound FL MRSA Sporadic
286 CBD0927 Nose FL MRSA USA 300
287 CBD0928 Nose FL MRSA Sporadic
288 CBD0929 Wound FL MRSA Sporadic
289 CBD0930 Wound FL MRSA USA 300
290 CBD0931 Wound FL MRSA Sporadic
291 CBD0932 Wound FL MRSA USA 300
292 CBD0933 Wound FL MRSA USA 300
293 CBD0934 Wound FL MRSA USA 100
294 CBD0935 Wound FL MRSA USA 300
295 CBD0936 Wound FL MRSA USA 100
296 CBD0937 Wound FL MRSA USA 300
297 CBD0938 Wound FL MRSA USA 300
298 CBD0939 Wound FL MRSA Sporadic
299 CBD0940 Wound FL MRSA USA 300
300 CBD0941 Wound FL MRSA USA 300
301 CBD0942 Wound FL MRSA USA 300
302 CBD0943 Wound FL MRSA Sporadic
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303 CBD0944 Wound FL MRSA Sporadic
304 CBD0945 Wound FL MRSA USA 300
305 CBD0946 Wound FL MRSA USA 300
306 CBD0947 Wound FL MRSA USA 300
307 CBD0948 Wound FL MRSA Sporadic
308 CBD0949 Wound FL MRSA USA 300
309 CBD0950 Wound FL MRSA Sporadic
310 CBD0951 Wound FL MRSA USA 300
311 CBD0952 Wound FL MRSA Sporadic
312 CBD0953 Wound FL MRSA USA 300
313 CBD0954 Wound FL MRSA Sporadic
314 CBD0955 Wound FL MRSA USA 300
315 CBD0956 Wound FL MRSA USA 300
316 CBD0957 Wound FL MRSA USA 300
317 CBD0958 Wound FL MRSA USA 300
318 CBD0959 Wound FL MRSA USA 300
319 CBD0960 Wound FL MRSA USA 100
320 CBD0961 Wound FL MRSA USA 300
321 CBD0963 Wound FL MRSA USA 300
322 CBD0964 Wound FL MRSA USA 300
323 CBD0965 Wound FL MRSA USA 300
324 CBD0966 Wound FL MRSA USA 300
325 CBD0967 Wound FL MRSA USA 300
326 CBD0968 Wound FL MRSA USA 100
327 CBD0969 Wound FL MRSA USA 100
328 CBD0970 Wound FL MRSA Sporadic
329 CBD0971 Wound FL MRSA USA 300
330 CBD0972 Wound FL MRSA USA 300
331 CBD0973 Unknown FL MRSA USA 300
332 CBD0974 Wound FL MRSA Sporadic
333 CBD0975 Wound FL MRSA USA 300
334 CBD0976 Wound FL MRSA USA 300
335 CBD0977 Wound FL MRSA USA 300
336 CBD0978 Wound FL MRSA USA 100
337 CBD0979 Nose FL MSSA Sporadic
338 CBD0997 Wound FL MRSA USA 300
339 CBD0998 Wound FL MRSA Sporadic
340 CBD0999 Wound FL MRSA USA 300
341 CBD1000 Wound FL MRSA USA 300
342 CBD1001 Wound FL MRSA USA 300
343 CBD1002 Wound FL MRSA USA 300
344 CBD1003 Wound FL MRSA USA 100
345 CBD1004 Wound FL MRSA USA 300
346 CBD1006 Wound FL MRSA USA 300
347 CBD1007 Wound FL MRSA USA 300
348 CBD1008 Wound FL MRSA USA 300
349 CBD1009 Wound FL MRSA USA 300
350 CBD1010 Wound FL MRSA USA 300
351 CBD1011 Wound FL MRSA USA 300
352 CBD1012 Wound FL MRSA USA 300
353 CBD1013 Wound FL MRSA Sporadic
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354 CBD1014 Wound FL MRSA USA 300
355 CBD1015 Wound FL MRSA USA 300
356 CBD1016 Wound FL MRSA Sporadic
357 CBD1017 Wound FL MRSA USA 300
358 CBD1018 Wound FL MRSA USA 300
359 CBD1019 Wound FL MRSA USA 300
360 CBD1020 Wound FL MRSA USA 100
361 CBD1021 Wound FL MRSA USA 300
362 CBD1022 Wound FL MRSA USA 300
363 CBD1023 Wound FL MRSA Sporadic
364 CBD1024 Wound FL MRSA USA 300
365 CBD1025 Wound FL MRSA USA 100
366 CBD1026 Wound FL MRSA USA 300
367 CBD1027 Wound FL MRSA Sporadic
368 CBD1028 Wound FL MRSA USA 300
369 CBD1029 Wound FL Intermediate USA 400
370 CBD1030 Wound FL MRSA USA 300
371 CBD1031 Wound FL MRSA USA 100
372 CBD1032 Unknown FL MRSA USA 300
373 CBD1033 Wound FL MRSA USA 300
374 CBD1034 Wound FL MRSA USA 300
375 CBD1035 Wound WA Borderline Sporadic
376 CBD1036 Wound WA MRSA USA 300
377 CBD1037 Wound WA MRSA USA 300
378 CBD1038 Wound WA MRSA Sporadic
379 CBD1039 Wound WA MRSA Sporadic
380 CBD1040 Wound WA MRSA USA 300
381 CBD1041 Wound WA MRSA USA 300
382 CBD1042 Wound WA MRSA USA 300
383 CBD1043 Sputum WA MRSA USA 100
384 CBD1044 Wound WA MRSA USA 300
385 CBD1045 Wound WA MRSA USA 300
386 CBD1046 Wound WA MRSA Sporadic
387 CBD1047 Wound WA MRSA USA 300
388 CBD1048 Wound WA MRSA Sporadic
389 CBD1049 Wound WA MRSA USA 100
390 CBD1050 Wound WA MRSA USA 300
391 CBD1051 Nose WA MRSA USA 300
392 CBD1052 Wound WA MRSA USA 300
393 CBD1053 Wound WA MRSA USA 300
394 CBD1054 Sputum WA MRSA USA 100
395 CBD1055 Wound WA MRSA Sporadic
396 CBD1064 USA 100 NARSA MRSA USA 100
397 CBD1065 USA 200 NARSA MRSA USA 200
398 CBD1066 USA 300 NARSA MRSA USA 300
399 CBD1067 USA 400 NARSA MRSA USA 400
400 CBD1068 USA 500 NARSA MRSA USA 500
401 CBD1069 USA 600 NARSA MRSA USA 600
402 CBD1070 USA 700 NARSA MRSA USA 700
403 CBD1071 USA 800 NARSA MRSA USA 800
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